AP733A - Arylsulfonylamino hydroxamic acid derivatives. - Google Patents

Arylsulfonylamino hydroxamic acid derivatives. Download PDF

Info

Publication number
AP733A
AP733A APAP/P/1997/001078A AP9701078A AP733A AP 733 A AP733 A AP 733A AP 9701078 A AP9701078 A AP 9701078A AP 733 A AP733 A AP 733A
Authority
AP
ARIPO
Prior art keywords
alkyl
aryl
amino
methoxybenzenesulfonyl
heteroaryl
Prior art date
Application number
APAP/P/1997/001078A
Other versions
AP9701078A0 (en
Inventor
Todd Andrew Blumenkopf
Ralph Pelton Robinson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP9701078A0 publication Critical patent/AP9701078A0/en
Application granted granted Critical
Publication of AP733A publication Critical patent/AP733A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

A compound of the formula wherein n, X, R3, R4 and Q are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, and other diseases characterized by matrix metalloprdteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.

Description

ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES
Background of the Invention
The present invention relates to arylsulfonylamino hydroxamic acid derivatives which are inhibitors of matrix metalioproteinases or the production of tumor necrosis factor (TNF) and as such are useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (hereinafter
NSAID'S) and analgesics for the treatment of arthritis, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and alkaloids, such as vincristine, in the treatment of cancer.
This invention also relates to a method of using such compounds in the treatment of the above diseases in mammals, especially humans, and to pharmaceutical compositions useful therefor.
There are a number of enzymes which effect the breakdown of structural proteins and which are structurally related metailoproteases. Matrix-degrading metalioproteinases, such as gelatinase, stromelysin and collagenase, are involved in tissue matrix degradation (e.g. collagen collapse) and have been implicated in many pathological conditions involving abnormal connective tissue and basement membrane matrix metabolism, such as arthritis (e.g. osteoarthritis and rheumatoid arthritis), tissue ulceration (e.g. comeal, epidermal and gastric ulceration), abnormal wound healing, periodontal disease, bone disease (e.g. Paget's disease and osteoporosis), tumor metastasis or invasion, as well as HIV-infection (J, Leuk. Biol.. 52 (2): 244-248, 1992).
Tumor necrosis factor is recognized to be involved in many infectious and autoimmune diseases (W. Fiers, FEBS Letters. 1991, 285. 199). Furthermore, it has been shown that TNF is the prime mediator of the inflammatory response seen in sepsis and septic shock (C.E. Spooner et al., Clinical Immunology and Immunopathology. 1992, 62 S11).
AP/P/ 9 7 / 0 1 0 78
AP. Ο Ο 7 3 3
-2Summary of the Invention
The present invention relates to a compound of the formula
II
HO-N-CH (CH2>n
-N
R‘ \//‘ s\ oZ/\ or the pharmaceutically acceptable salts thereof, wherein n is 1 to 6;
X is OR1 wherein R1 is as defined below; azetidinyl, pyrrolidinyi, piperidinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, piperazinyl or a bridged diazabicycloalkyl ring selected from the group consisting of
(CH2)p
AP/P/ 9 7 / 0 1 0 78
AP. 0 0 73 3
d e wherein r is 1, 2 or 3; m is 1 or 2; and p is 0 or 1;
wherein each heterocyclic group may optionally be substituted by one or two groups 15 selected from hydroxy, (C,-Ce)alkyl, (C^C^alkoxy, (C1-C10)a^l, (C^C^acyloxy, (C6C10)aryl, (C5-C9)heteroaryl, (C6-C10)aryl(CrC6)alkyl, (C5-Cg)heteroaryl (CrC6)alkyl, hydroxy (C1-Ce)alkyl, (C^CJalkoxy (C^-C^alkyl, (Cl-C6)acyloxy(C1-C6)alkyl, (Cr C6)alkylthio, (C.,-C6)alkylthio (C,-Ce)alkyl, (C6-C10)arylthio, (C6-C10) arylthio(C.,-C6)alkyl, R9R10N, R9R10NSO2i R9R10NCO, R’R10NCO(C,-Ce)alkyl wherein R9 and R10 are each independently hydrogen, (C^-C^alkyl, (C6-C10)aryl, (C5-C9)heteroaryl, (C6-C10)aryl (C,C6)alkyl or (C5-C9)heteroaryl (C^-CJalkyl or R9 and R10 may be taken together with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl, piperidinyl, morpholinyi orthiomorpolinyl ring; R12SO2, R12SO2NH wherein R12 is trifluoromethyl, (C,C6)alkyl, (C6-C10)aryl, (C5-C9)heteroaryl, (Cg-CJaryl^-C^aikyl or(C5-C9)heteroaryl (Cr
C6)alkyl; R13CONR9 wherein R9 is as defined above and R13 is hydrogen, (C1-C6)alkyl, (C^CeJalkoxy, (C6-C10)aryl, (C5-C9)heteroaryl, (CrCJaryKCrCJalkyliCg-C^aryKC,C6)alkoxy or (Cj-C^heteroaryKC^CeJalkyl; R14OOC, R^OOCiC^Cgjalkyl wherein R14 is (C^CJaikyl, (C6-C10)aryl, (C5-C9)heteroaryl, (C6-C10)aryl (C,-C6)alkyl, 5-indanyl, CHR5OCOR6 wherein R5 is hydrogen or (C^CJalkyl and R6 is (C^CeJalkyl, (Cr
C6)alkoxy or (C6-C10)aryl; CH2CONR7R8 wherein R7 and R8 are each independently hydrogen or (C,-Ce)alkyl or may be taken together with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl, piperidinyl, morpholinyi or thiomorpholinyl
AP/P/ 9 7 / 0 1 0 78
AP. Ο Ο 7 3 3
-4ring; or R1SO (C.,CB)alkyl wherein R15 is H2N(CHR16)CO wherein R16 is the side chain of a natural D- or L-amino acid;
R1 is (C6-C10)aryl, (C5-C9)heteroaryl, (C6-C10)aryl(C1-C6)alkyl, 5-indanyl, CHR5OCOR6 or CH2CONR7R8 wherein Rs, R6, R7 and R8 are as defined above;
R3 and R4 are each independently selected from the group consisting of hydrogen, (C^C^alkyl, trifluoromethyl, trifluoromethyKC^C^alkyl, (C^-C^alkyl (difluoromethylene), (C1-C3)alkyl(difluoromethylene)(C1-C3)alkyl, (C6-C10)aryl, (C5C9)heteroaryl, (Cg-CJaryKC^-Cgjalkyl, (Cj-CgjheteroaryKC^Cgjalkyl, (C6-C10)aryl(C6C10)aryl, (C3-C6)cycloalkyl, (Cj-C^cycloalkyKC,C6)alkyl,hydroxy(C,-C6)alkyl, (C^-CJacyloxy^-C^alkyl, (C^^alkoxyiC^C^alkyl, (C,C10)acylamino(C,-C6)alkyl, piperidyl, (C^CJalkylpiperidyl, (Cg-C^JaryKC^CgJalkoxyiC,C6)alkyl, (Cg-CgjheteroaryKC^CJalkoxyCC^C^alkyl, (C^CgJalkylthioCC^CJalkyl, (C6C^arylthioCC^-CJalkyl, (C^C^alkylsulfinyKC^-CJalkyl, (Cg-C^JarylsulfinyKC^CgJalkyl, (C^CgJalkylsulfonyKC^Cgjalkyl, (Cg-C^JarylsulfonyKC^CgJalkyl, aminoiC^CgJalkyl, (C,CgJalkylaminoiC^Cgjalkyl, ((C1-C6)alkylamino)2(C1-C6)alkyl, R^COfC^-CgJalkyl wherein R17 is R14O or R7R8N wherein R7, R8 and R14 are as defined above; or R18(C,-Ce)alkyl wherein R18 is piperazinyl, (C^-C^acylpiperazinyl, (C6-C10)arylpiperazinyl, (C5C9)heteroarylpiperazinyl, (C,-C6)alkylpiperazinyl, (C6-C10)aryl(CrC6)alkylpiperazinyl, (C5CgJheteroaryKC^Cgjalkylpiperazinyl, morpholinyl, thiomorpholinyl, piperidinyl, pyrrolidinyl, piperidyl, (C,-C6) alkylpiperid yl, (C6-C10)arylpiperidyl, (C5C9)heteroarylpiperidyl, (Cg-C^JaryKC^CgJalkylpiperidyl, (Cg-CJheteroarylfC,C6)alkylpiperidyl or (C,-C,0)acylpiperidyl;
or R3 and R4 may be taken together to form a (C3-C6)cycloalkyl, oxacyclohexyl, thiocyclohexyl, indanyl or tetralinyl ring or a group of the formula
AP/P/ 9 7 / 0 1 0 7 8
hr
R21 wherein R21 is hydrogen, (C,-C10)acyl, (C^Cgjalkyl, (C6-C10)aryl(C,-C6)alkyl, (C5CgjheteroaryKC^Cgjalkyl or (C^Cgjalkylsulfonyl; and
AP.0 0 7 3 3
-5Q is (C^Csjalkyl, (C6-C10)aryl, (C6-C10)aryloxy(C6-C10)aryl, (C6-C10)aryl(C6C10)aryl, (Ce-C10)aryl(C6-Cw)aiyl(CrC6)alkyl, (C6-C10)aryioxy(C5-C9)heteroaryl, (C5C9)heteroaryl, (C,-C6)alkyl(C6-C10)aryl, (C^-CJalkoxyiCg-C^aryl, (C6-C10)aryl(Cr C6)alkoxy(C6-C10)aryl, (C6-C10)aryl(C1-C6)alkoxy(C1-C6)alkyl, (Cs-C9)heteroaryloxy(Ce5 C10)aryl, (C^CJalkykCg-CJheteroaryl, (C^CgJalkoxyiCj-CJheteroaryl, (Cg-C^aryKC,C6)alkoxy(C5-C9)heteroaryl, (C5-C9)heteroaryloxy(C5-C9)heteroaryl, (C6-C1o)aryloxy(C1C6)alkyl, (Cg-CglheteroaryloxyiC^CJalkyl, (C1-C6)aIkyl(C6-C10)aryloxy(C6-C10)aryl, (Cr C6)alkyl(Cs-C9)heteroaryloxy(C6-C10)aryl, (C1-C6)alkyl(C6-C,0)aryloxy(C5-C9)heteroaryl, (C1-C6)alkoxy(C6-C10)aryloxy(C6-C10)aryl, (C^CJalkoxyiCg-CglheteroaryloxytCg-C^aryl or (C1-C6)alkoxy(C6-C10)aryloxy(C5-C9)heteroaryl wherein each aryl group is optionally substituted by fluoro, chloro, bromo, ((^-CJalkyl, (C^Cgjalkoxy or perfluoro^-Cgjalkyl;
with the proviso that X must be substituted when defined as azetidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, piperazinyl, (C,-C10)acylpiperazinyl, (C^CJalkylpiperazinyl, (C615 C10)arylpiperazinyl, (C5-Cg)heteroarylpiperazinyl ora bridged diazabicycloalkyl ring.
The term alkyl, as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof.
The term alkoxy, as used herein, includes O-alkyl groups wherein alkyl is defined above.
The term aryl, as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl, optionally substituted by 1 to 3 substituents selected from the group consisting of fluoro, chloro, trifiuoromethyl, (C,-C6)alkoxy, (C6-Cw)aryloxy, trifluoromethoxy, difluoromethoxy and (C^CJalkyl.
The term heteroaryl, as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic heterocyclic compound by removal of one hydrogen, such as pyridyl, furyl, pyroyl, thienyl, isothiazolyl, imidazolyl, benzimidazolyl, tetrazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinolyl, benzofuryl, isobenzofuryl, benzothienyl, pyrazolyl, indolyl, isoindolyl, purinyl, carbazolyl, isoxazolyl, thiazolyl, oxazolyl, benzthiazolyl or benzoxazolyl, optionally substituted by 1 to 2 substituents selected from the group consisting of fluoro, chloro, trifiuoromethyl, (C,-C6)alkoxy, (C6C10)aryloxy, trifluoromethoxy, difluoromethoxy and (C.,-C6)alkyl.
AP/P/ 9 7 / 0 1 0 78
AP . 0 0 7 3 3
-6The term acyl, as used herein, unless otherwise indicated, includes a radical of the general formula RCO wherein R is alkyl, alkoxy, aryl, arylalkyl or arylalkyloxy and the terms alkyl or aryl are as defined above.
The term acyloxy, as used herein, includes O-acyl groups wherein acyl is 5 defined above.
The term D- or L-amino acid, as used herein, unless otherwise indicated, includes glycine, alanine, valine, leucine, isoleucine, phenylalanine, asparagine, glutamine, tryptophan, proline, serine, threonine, tyrosine, hydroxyproline, cysteine, cystine, methionine, aspartic acid, glutamic acid, lysine, arginine or histidine.
The compound of formula I may have chiral centers and therefore exist in different enantiomeric forms. This invention relates to all optical isomers and stereoisomers of the compounds of formula I and mixtures thereof.
Preferred compounds of formula I include those wherein n is 2.
Other preferred compounds of formula I include those wherein either R3 or R4 is not hydrogen.
Other preferred compounds of formula I include those wherein Ar is (C,C6)alkoxy(C6-C10)aryl,(C6-C10)aryl(C,-C6)alkoxy(C6-C10)aryl,4-fluorophenoxy(C6-C10)aryl, 4-fluorobenzyloxy(C6-C10)aryl or (C^C^alkyKCg-C^jaryloxyiCg-C^jaryl.
Other preferred compounds of formula I include those wherein X is indolinyl or 20 piperidinyl.
More preferred compounds of formula I include those wherein n is 2; either R3 or R4 is not hydrogen; Ar is (C,-C6)alkoxy(C6-C10)aryl, (Ce-C^aryliC^-C^alkoxyiCeC10)aryl, 4-fluorophenoxy(C6-C10)aryl, 4-fluorobenzyloxy(C6-C10)aryi or (C^CgjalkykCgC10)aryloxy(C6-C10)aryl; and X is indolinyl or piperidinyl.
Specific preferred compounds of formula I include the following:
3-[(Cyclohexylhydroxycarbamoylmethyl)-(4-methoxybenzenesulfonyl)-amino]propionic acid indan-5-yl ester;
Acetic acid 1 -{3-[(1 -hydroxycarbamoyl-2-methylpropyl)-(4-methoxy-benzenesulfonyl)-amino]propionyl}piperidin-4-yl ester;
2-Cyclohexyl-N-hydroxy-2-[[3-(4-hydroxypiperidin-1 -yl)-3-oxopropyl]-(4-methoxy-benzenesulfonyl)amino]acetamide;
Benzoic acid 1-{3-[(1-hydroxycarbamoyl-2-methylpropyl)-(4-methoxy-benzenesulfonyl)amino]propionyl}piperidin-4-yl ester;
AP/P/ 9 7 / 0 1 0 78
AP.00733
-7N-Hydroxy-2-[[3-(4-hydroxypiperidin-1-yl)-3-oxopropyl]-(4-methoxybenzenesulfonyl)amino]-3-methylbutyramide;
1- {3-[(Cyclohexylhydroxycarbamoylmethyl)-(4-methoxybenzenesulfonyl)-amino]propionyl}piperidine-4-carboxylic acid;
1-{3-[(Cyclohexylhydroxycarbamoylmethyl)-(4-methoxybenzenesulfonyl)amino]propionyl}piperidine-4-carboxylic acid ethyl ester;
2- Cyclohexyl-N-hydroxy-2-{(4-methoxybenzenesuIfonyl)-[3-(4-methylaminopiperidin-1-yl)-3-oxopropyl]amino}acetamide;
3- (4-Chlorophenyl)-N-hydroxy-2-{(4-methoxybenzenesulfonyl)10 [3-(4-methylaminopiperidin-1 -yl)-3-oxopropyl]amino}propionamide;
3- Cyclohexyl-N-hydroxy-2-{(4-methoxybenzenesulfonyl)-[3-(4-methylaminopiperidin-1-yl)-3-oxopropyl]amino}propionamide;
N-Hydroxy-2-[(3-[4-(2-hydroxy-2-methylpropyl)piperazin-1-yl]3-oxopropyl}-(4-methoxy-benzenesulfonyl)amino]-3-methylbutyramide;
2,2-Dimethylpropionic acid 2-(4-(3-((1-hydroxycarbamoyl-2-methylpropyl)-(4methoxy-benzenesulfonyl)amino]propionyl}piperazin-1 -yl)ethyI ester, and
Benzoic acid 2-(4-{3-[(1 -hydroxycarbamoyl-2-methylpropyl)-(4-methoxybenzenesulfonyl)-amino]propionyl}piperazin-1 -yl)-ethyI ester.
Other specific compounds of formula I include the following;
2-Cy clohexyl-N-hyd roxy-2-[{3-[4-(2-hydroxy ethy I) pipe razin1-yl]-3-oxopropyl}-(4-methoxybenzenesulfonyl)amino]acetamide;
N-Hydroxy-2-[(3-[5-(2-hydroxyethyl)-2,5-diazabicyclo[2.2.1 ]hept-2-yl]-3-oxopropyl}-(4-methoxybenzenesulfonyl)amino]-3-methylbutyramide;
2-((4-Benzy loxy benzen esulfonyl) -[3- (4-hydroxy pipe rid in-1 -yl)25 3-oxopropyl]amino}-N-hydroxy-3-methylbutyramide;
2-Cyclohexyl-2-([4-(4-fluorophenoxy)benzenesulfonyl]-(3-(4-hydroxypiperidin-1-yl)-3-oxopropyl]-amino}-N-hydroxyacetamide;
2-((4-(4-Butylphenoxy) benzenesulfony l]-[3-(4-hydroxypiperidin1-yl)-3-oxopropyl]-amino}-N-hydroxy-3-methylbutyramide;
1 -{(4-Methoxybenzenesulfonyl)-[3-(4-methylaminopiperidin-1 -yl)-3-oxopropyl]amino}-cyclopentanecarboxylic acid hydroxyamide;
4- (3-(( 1-Hydroxy carbamoyl-2-methyl pro py I)-(4-m eth oxy benzenesulfonyl)amino]-propionyl}piperazine-2-carboxylic acid ethyl ester;
AP/P/ 9 7 / 0 1 0 78
ΑΡ ο 0 73 3
-83-[(Cyclo hexyl hydroxy carbarn oy I methyl)-(4-methoxy be nzenesulfonyl)amino]propionic acid ethoxycarbonyloxymethyl ester;
3-[(1-Hydroxycarbamoylpentyl)-(4-methoxybenzenesulfonyl)amino]propionic acid ethoxycarbonyloxymethyl ester;
3-[[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-(1-hydroxycarbamoyl-2-methyl-propyl)-amino]-propionic acid ethoxycarbonyloxymethyl ester; and
3-[[4-(4-Fluorophenoxy)-benzenesulfonyl]-(1-hydroxycarbamoyl-2methyl-propyl)-amino]-propionic acid ethoxycarbonyloxymethyl ester.
The present invention also relates to a pharmaceutical composition for (a) the treatment of a condition selected from the group consisting of arthritis, cancer, synergy with cytotoxic anticancer agents, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, in combination with standard NSAID’S and analgesics and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) or (b) the inhibition of matrix metalloproteinases or the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising an amount of a compound of formula I or a pharmaceutically acceptable salt thereof effective in such treatments and a pharmaceutically acceptable carrier.
The present invention also relates to a method for the inhibition of (a) matrix metalloproteinases or (b) the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
The present invention also relates to a method for treating a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, compounds of formula I may be used in combination with standard NSAID’S and analgesics and in combination with cytotoxic anticancer agents, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an amount of a compound of formula I or a pharmaceutically acceptable salt thereof effective in treating such a condition.
AP/P/ 97/01078
AP.00733
-9Detailed Description of the Invention
The following reaction Schemes illustrate the preparation of the compounds of the present invention. Unless otherwise indicated n, R3, R4, X and Ar in the reaction Schemes and the discussion that follow are defined as above.
Scheme 1
AP/P/97 / 0 1 0 78
III
ΑΡ..0 0 7 3 3
-10Scheme 1 cont'd
AP/P/ 9 7 / 0 1 0 78
I
AP . 0 0 7 3 3
-11Scheme 2
viii
AP/P/ 97 / 0 1 0 78
IX iv
AP. j) Ο 7 3 3
-12Scheme 2 (continued)
IV
I
I
AP/P/ 97 / 0 1 0 78
I
AP.00733
-13ln reaction 1 of Scheme 1, the amino acid compound of formula VII, wherein R16 is (C.,-C6)alkyl, benzyl, allyl or tert-butyl, is converted to the corresponding compound of formula VI by reacting VII with a reactive functional derivative of an arylsulfonic acid compound, such as an arylsulfonyl chloride, in the presence of a base, such as triethylamine, and a polar solvent, such as tetrahydrofuran, dioxane, water or acetonitrile, preferably a mixture of dioxane and water. The reaction mixture is stirred, at room temperature, for a time period between about 10 minutes to about 24 hours, preferably about 60 minutes.
In reaction 2 of Scheme 1, the arylsulfonyl amino compound of formula VI, 10 wherein R16 is (C^CgJalkyl, benzyl, allyl or tert-butyl, is converted to the corresponding compound of formula V, wherein n is 1, 3, 4, 5 or 6, by reacting VI with a reactive derivative of an alcohol of the formula
O „ ll
R”-OC-(CHj)„-OH such as the chloride, bromide or iodide derivative, preferably the iodide derivative, wherein the R17 protecting group is (C^-C^alkyl, benzyl, allyl or tert-butyl, in the presence of a base such as potassium carbonate or sodium hydride, preferably sodium hydride, and a polar solvent, such as dimethylformamide. The reaction mixture is stirred, at room temperature, for a time period between about 60 minutes to about 48 hours, preferably about 18 hours. The R17 protecting group is chosen such that it may be selectively removed in the presence of and without loss of the R16 protecting group, therefore, R17 cannot be the same as R16. Removal of the R17 protecting group from the compound of formula V to give the corresponding carboxylic acid of formula IV, in reaction 3 of Scheme 1., is carried out under conditions appropriate for that particular R17 protecting group in use which will not affect the R16 protecting group. Such conditions include; (a) saponification where R17 is (C^Cgjalkyl and R16 is tert-butyl, (b) hydrogenolysis where R’7 is benzyl and R16 is tert-butyl or (C^CgJalkyl, (c) treatment with a strong acid, such as trifluoroacetic acid or hydrochloric acid where R17 is tert30 butyl and R16 is (C,-C6)alkyl, benzyl or allyl, or (d) treatment with tributyltinhydride and acetic acid in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride where R17 is allyl and R16 is (CrC6)alkyl, benzyl or tert-butyl.
In reaction 4 of Scheme 1, the carboxylic acid of formula IV is condensed with a compound of the formula HX or the salt thereof, wherein X is as defined above, to
AP/P/ 9 7 / 0 1 0 78
ΑΡ..0 ο 73 3
-14give the corresponding amide compound of formula III. The formation of amides from primary or secondary amines or ammonia and carboxylic acids is achieved by conversion of the carboxylic acid to an activated functional derivative which subsequently undergoes reaction with a primary or secondary amine or ammonia to form the amide. The activated functional derivative may be isolated prior to reaction with the primary or secondary amine or ammonia. Alternatively, the carboxylic acid may be treated with oxalyl chloride or thionyl chloride, neat or in an inert solvent, such as chloroform, at a temperature between about 25°C to about 80°C, preferably about 50°C, to give the corresponding acid chloride functional derivative. The inert solvent and any remaining oxalyl chloride or thionyl chloride is then removed by evaporation under vacuum. The remaining acid chloride functional derivative is then reacted with the primary or secondary amine or ammonia in an inert solvent, such as methylene chloride, to form the amide. The preferred method for the condensation of the carboxylic acid of formula IV with a compound of the formula HX, wherein X is as defined above, to provide the corresponding compound of formula III is the treatment of IV with (benzotriazol-l-yloxy)tris(dimethylamino) phosphonium hexafluorophosphate in the presence of a base, such as triethylamine, to provide the benzotriazol-1-oxy ester in situ which, in turn, reacts with the compound of the formula HX, in an inert solvent, such as methylene chloride, at room temperature to give the compound of formula III.
Removal of the R16 protecting group from the compound of formula III to give the corresponding carboxylic acid of formula II, in reaction 5 of Scheme 1, is carried out under conditions appropriate for the particular R16 protecting group in use. Such conditions include; (a) saponification where R16 is lower alkyl, (b) hydrogenolysis where R16 is benzyl, (c) treatment with a strong acid, such as trifluoroacetic acid or hydrochloric acid, where R16 is tert-butyl, or (d) treatment with tributyltinhydride and acetic acid in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride where R16 is allyl.
In reaction 6 of Scheme 1, the carboxylic acid compound of formula II is converted to the hydroxamic acid compound of formula I by treating II with 1-(330 dimethylaminopropyl)-3-ethylcarbodiimide and 1-hydroxybenztriazole in a polar solvent, such as dimethylformamide, followed by the addition of hydroxylamine to the reaction mixture after a time period between about 15 minutes to about 1 hour, preferably about 30 minutes. The hydroxylamine is preferably generated in situ from a salt form, such
AP/P/ 9 7 / 0 1 0 78
AP .0 0 7 3 3
-15as hydroxylamine hydrochloride, in the presence of a base, such as Nmethylmorpholine. Alternatively, a protected derivative of hydroxylamine or its salt form, where the hydroxyl group is protected as a tert-butyl, benzyl, allyl or trimethylsilylether, may be used in the presence of (benzotriazol-1-yloxy)tris5 (dimethylamino) phosphonium hexafluorophosphate and a base, such as Nmethylmorpholine. Removal of the hydroxylamine protecting group is carried out by hydrogenolysis for a benzyl protecting group or treatment with a strong acid, such as trifiuoroacetic acid, for a tert-butyl protecting group. The allyl protecting group may be removed by treatment with tributyltinhydride and acetic acid in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride. The 2-trimethylsilylethyl ether may be removed by reaction with a strong acid, such as trifiuoroacetic acid or by reaction with a fluoride source such as boron trifluoride etherate. N.O-bis(4-methoxybenzyl)hydroxylamine may also be used as the protected hydroxylamine derivative where deprotection is achieved using a mixture of methanesulfonic acid and trifiuoroacetic acid.
In reaction 1 of Scheme 2, the arylsulfonylamino compound of formula VI, wherein R16 is (C,-Ce)alkyl, benzyl or tert-butyl, is converted to the corresponding compound of formula VIII by reacting VI with a reactive functional derivative, such as the halide, preferably the iodide derivative, of 3-(tert-butyldimethyIsilyloxy)-1 -propanol in the presence of a base, such as sodium hydride. The reaction is stirred in a polar solvent, such as dimethylformamide, at room temperature, for a time period between about 2 hours to about 48 hours, preferably about 18 hours.
In reaction 2 of Scheme 2, the compound of formula VIII is converted to the alcohol compound of formula IX by treatment of VIII with an excess of an acid, such as acetic acid, or an excess of a Lewis acid, such as boron trifluoride etherate. When using an acid, such as acetic acid, water is added and a water-soluble cosolvent, such as tetrahydrofuran, can be added to promote solubility. The reaction is stirred for a time period between about 18 hours to about 72 hours, preferably about 24 hours, at a temperature between about room temperature to about 60°C, preferably about 50°C. When using a Lewis acid, such as boron trifluoride etherate, the reaction is stirred in a solvent, such as methylene chloride, for a time period between about 10 minutes to about 6 hours, preferably about 20 minutes, at a temperature between about -20°C to about room temperature, preferably about room temperature.
AP/P/ 9 7 / 0 1 0 78
AP.D 0 7 3 3
-16ln reaction 3 of Scheme 2, the alcohol compound of formula IX is oxidized to the carboxylic acid compound of formula IV, wherein n is 2, by reacting IX with an excess of sodium periodate and a catalytic amount of ruthenium trichloride in a solvent mixture consisting of acetonitrile, water and carbon tetrachloride, at room temperature, for a time period between about 1 hour to about 24 hours, preferably about 4 hours.
The compound of formula IV, wherein n is 2, is further reacted to provide the hydroxamic acid compound of formula I, wherein n is 2, according to the procedure described above in reactions 4, 5 and 6 of Scheme 1.
Pharmaceutically acceptable salts of the acidic compounds of the invention are 10 salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethyl-ammonium, diethylammonium, and tris(hydroxymethyl)-methylammonium slats.
Similarly acid addition salts, such as of mineral acids, organic carboxylic and 15 organic sulfonic acids e.g. hydrochloric acid, methanesulfonic acid, maleic acid, are also possible provided a basic group, such as pyridyl, constitutes part of the structure.
The ability of the compounds of formula I or their pharmaceutically acceptable salts (hereinafter also referred to as the compounds of the present invention) to inhibit matrix metalloproteinases or the production of tumor necrosis factor (TNF) and, consequently, demonstrate their effectiveness for treating diseases characterized by matrix metalloproteinase or the production of tumor necrosis factor is shown by the following in vitro assay tests.
Biological Assay
Inhibition of Human Collaqenase (MMP-1)
Human recombinant collagenase is activated with trypsin using the following ratio: 10 pg trypsin per 100 pg of collagenase. The trypsin and collagenase are incubated at room temperature for 10 minutes then a five fold excess (50 //g/10 /zg trypsin) of soybean trypsin inhibitor is added.
mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted using the following Scheme:
mM-> 120 pM-> 12 μΜ-> 1.2 μΜ-> 0.12 μΜ
Twenty-five microliters of each concentration is then added in triplicate to appropriate wells of a 96 well microfluor plate. The final concentration of inhibitor will
AP/P/ 9 7 / 0 1 0 78
AP. Ο Ο 7 3 3
-17be a 1:4 dilution after addition of enzyme and substrate. Positive controls (enzyme, no inhibitor) are set up in wells D1-D6 and blanks (no enzyme, no inhibitors) are set in wells D7-D12.
Collagenase is diluted to 400 ng/ml and 25 μΙ is then added to appropriate wells of the microfluor plate. Final concentration of collagenase in the assay is 100 ng/ml.
Substrate (DNP-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH2) is made as a 5 mM stock in dimethyl sulfoxide and then diluted to 20 μΜ in assay buffer. The assay is initiated by the addition of 50 μΙ substrate per well of the microfluor plate to give a final concentration of 10 μΜ.
Fluorescence readings (360 nM excitation, 460 nm emission) were taken at time 0 and then at 20 minute intervals. The assay is conducted at room temperature with a typical assay time of 3 hours.
Fluorescence vs time is then plotted for both the blank and collagenase 15 containing samples (data from triplicate determinations is averaged). A time point that provides a good signal (the blank) and that is on a linear part of the curve (usually around 120 minutes) is chosen to determine ICM values. The zero time is used as a blank for each compound at each concentration and these values are subtracted from the 120 minute data. Data is plotted as inhibitor concentration vs % control (inhibitor fluorescence divided by fluorescence of collagenase alone x 100). IC^’s are determined from the concentration of inhibitor that gives a signal that is 50% of the control.
If ICjo’s are reported to be <0.03 μΜ then the inhibitors are assayed at concentrations of 0.3 μΜ, 0.03 μΜ, 0.03 μΜ and 0.003 μΜ.
Inhibition of Gelatinase (MMP-2)
Inhibition of gelatinase activity is assayed using the Dnp-Pro-Cha-Gly-Cys(Me)His-Ala-Lys(NMA)-NH2 substrate (10 μΜ) under the same conditions as inhibition of human collagenase (MMP-1).
72kD gelatinase is activated with 1 mM ΑΡΜΑ (p-aminophenyl mercuric acetate) for 15 hours at 4°C and is diluted to give a final concentration in the assay of 100 mg/ml. Inhibitors are diluted as for inhibition of human collagenase (MMP-1) to give final concentrations in the assay of 30 μΜ, 3 μΜ, 0.3 μΜ and 0.03 μΜ. Each concentration is done in triplicate.
AP/P/ 9 7 / 0 1 0 78
AP. Ο Ο 7 3 3
-18Fluorescence readings (360 nm excitation, 460 emission) are taken at time zero and then at 20 minutes intervals for 4 hours.
ICgo's are determined as per inhibition of human coliagenase (MMP-1). If IC^s are reported to be less than 0.03 μΜ, then the inhibitors are assayed at final concentrations of 0.3 μΜ, 0.03 pM, 0.003 μΜ and 0.003 μΜ.
Inhibition of Stromelvsin Activity (MMP-3)
Inhibition of stromelysin activity is based on a modified spectrophotometric assay described by Weingarten and Feder (Weingarten, H. and Feder, J., Spectrophotometric Assay for Vertebrate Coliagenase, Anal. Biochem. 147, 437-440 (1985)). Hydrolysis of the thio peptolide substrate [Ac-Pro-Leu-GlySCH[CH2CH(CH3)2]CO-Leu-Gly-OC2H5] yields a mercaptan fragment that can be monitored in the presence of Ellman’s reagent.
Human recombinant prostromelysin is activated with trypsin using a ratio of 1 μϊ of a 10 mg/ml trypsin stock per 26 μg of stromelysin. The trypsin and stromelysin are incubated at 37°C for 15 minutes followed by 10 μΙ of 10 mg/ml soybean trypsin inhibitor for 10 minutes at 37°C for 10 minutes at 37°C to quench trypsin activity.
Assays are conducted in a total volume of 250 μϊ of assay buffer (200 mM sodium chloride, 50 mM MES, and 10 mM calcium chloride, pH 6.0) in 96-well microliter plates. Activated stromelysin is diluted in assay buffer to 25 pg/ml. Ellman’s reagent (3-Carboxy-4-nitrophenyl disulfide) is made as a 1M stock in dimethyl formamide and diluted to 5 mM in assay buffer with 50 μϊ per well yielding at 1 mM final concentration.
mM stock solutions of inhibitors are made in dimethyl sulfoxide and diluted serially in assay buffer such that addition of 50 μϊ- to the appropriate wells yields final concentrations of 3 μΜ, 0.3 μΜ, 0.003 μΜ, and 0.0003 μΜ. All conditions are completed in triplicate.
A 300 mM dimethyl sulfoxide stock solution of the peptide substrate is diluted to 15 mM in assay buffer and the assay is initiated by addition of 50 μϊ to each well to give a final concentration of 3 mM substrate. Blanks consist of the peptide substrate and Ellman’s reagent without the enzyme. Product formation was monitored at 405 nm with a Molecular Devices UVmax plate reader.
IC50 values were determined in the same manner as for coliagenase.
AP/P/ 97 / 0 1 0 78
AP. Ο Ο 7 3 3
-19Inhibition of MMP-13
Human recombinant MMP-13 is activated with 2mM ΑΡΜΑ (p-aminophenyl mercuric acetate) for 1.5 hours, at 37°C and is diluted to 400 mg/ml in assay buffer (50 mM Tris, pH 7.5, 200 mM sodium chloride, 5mM calcium chloride, 20/zM zinc chloride,
0.02% brij). Twenty-five microliters of diluted enzyme is added per well of a 96 well microfluor plate. The enzyme is then diluted in a 1:4 ratio in the assay by the addition of inhibitor and substrate to give a final concentration in the assay of 100 mg/ml.
mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted in assay buffer as per the inhibitor dilution scheme for inhibition of human collagenase (MMP-1): Twenty-five microliters of each concentration is added in triplicate to the microfluor plate. The final concentrations in the assay are 30 μΜ, 3pM, 0.3 pM, and 0.03 μΜ.
Substrate (Dnp-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH2) is prepared asfor inhibition of human collagenase (MMP-1) and 50 μ\ is added to each well to give a final assay concentration of 10 μΜ. Fluorescence readings (360 nM excitation; 450 emission) are taken at time 0 and every 5 minutes for 1 hour.
Positive controls consist of enzyme and substrate with no inhibitor and blanks consist of substrate only.
ICgo’s are determined as per inhibition of human collagenase (MMP-1). If IC^'s are reported to be less than 0.03 μΜ, inhibitors are then assayed at final concentrations of 0.3 μΜ, 0.03 pM, 0.003 pM and 0.0003 μΜ.
Inhibition of TNF Production
The ability of the compounds or the pharmaceutically acceptable salts thereof to inhibit the production of TNF and, consequently, demonstrate their effectiveness for treating diseases involving the production of TNF is shown by the following in vitro assay:
Human mononuclear cells were isolated from anti-coagulated human blood using a one-step Ficoll-hypaque separation technique. (2) The mononuclear cells were washed three times in Hanks balanced salt solution (HBSS) with divalent cations and resuspended to a density of 2 x 106 /ml in HBSS containing 1% BSA. Differential counts determined using the Abbott Cell Dyn 3500 analyzer indicated that monocytes ranged from 17 to 24% of the total cells in these preparations.
AP/P/ 9 7 / 0 1 0 78
AP ._ Ο Ο 7 3 3
-20180/y of the cell suspension was aliquoted into flate bottom 96 well plates (Costar). Additions of compounds and LPS (100ng/ml final concentration) gave a final volume of 200//1. All conditions were performed in triplicate. After a four hour incubation at 37°C in an humidified CO2 incubator, plates were removed and centrifuged (10 minutes at approximately 250 x g) and the supernatants removed and assayed for TNFa using the R&D ELISA Kit.
For administration to mammals, including humans, for the inhibition of matrix metalloproteinases or the production of tumor necrosis factor (TNF), a variety of conventional routes may be used including orally, parenterally and topically. In general, the active compound will be administered orally or parenteral'y at dosages between about 0.1 and 25 mg/kg body weight of the subject to be treated per day, preferably from about 0.3 to 5 mg/kg. However, some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
The compounds of the present invention can be administered in a wide variety of different dosage forms, in genera!, the therapeutically effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.
For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably com, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelation and acacia.
Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules: preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof. In the case of animals, they are
AP/P/ 97/01078
AP.Λ Ο 7 3 3
-21advantageously contained in an animal feed or drinking water in a concentration of 55000 ppm, preferably 25 to 500 ppm.
For parenteral administration (intramuscular, intraperitoneal, subcutaneous and intravenous use) a sterile injectable solution of the active ingredient is usually prepared.
Solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably adjusted and buffered, preferably at a pH of greater than 8, if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art. In the case of animals, compounds can be administered intramuscularly or subcutaneously at dosage levels of about 0.1 to 50 mg/kg/day, advantageously 0.2 to 10 mg/kg/day given in a single dose or up to
3 divided doses.
The present invention is illustrated by the following examples, but it is not limited to the details thereof.
EXAMPLE 1
2-Cyclohexvl-N-hydroxv-2-((4-methoxvbenzenesulfonvO-r3-(4-methvl-aminopipe ridin-1-vD-3-oxopropvnamino)acetamide (A) To a solution of D-cyclohexylgycine benzyl ester hydrochloride (17.0 grams,
59.9 mmol) and triethylamine (17.6 mL, 126.3 mmol) in water (60 mL) and 1,4-dioxane (100 mL) was added 4-methoxybenzenesulfonyl chloride (13.0 grams, 62.9 mmol). The mixture was stirred at room temperature for 16 hours and then most of the solvent was removed by evaporation under vacuum. The mixture was diluted with ethyl acetate and was washed successively with dilute hydrochloric acid solution, water, saturated sodium bicarbonate solution, and brine. The organic solution was dried over magnesium sulfate and concentrated to leave N-(4-methoxybenzenesulfonyl)-D-cyclohexylglycine benzyl ester as a white solid, 24.51 grams (99%).
(B) N-(4-Methoxybenzenesulfonyl)-D-cyclohexylglycine benzyl ester (12.0 grams,
29.16 mmol) was added to a suspension of sodium hydride (0.78 grams, 32.5 mmol) in dry Ν,Ν-dimethylformamide (100 ml) and, after 20 minutes, tert-butyl-(3-iodopropoxy)-dimethylsilane(9.2 grams, 30.6 mmol) was added. The
AP/P/ 9 7 / 0 1 0 78
AP . Ο Ο 7 3 3
-22resulting mixture was stirred at room temperature for 16 hours and was then quenched by addition of saturated ammonium chloride solution. The Ν,Ν-dimethylformamide was then removed by evaporation under vacuum. The residue was taken up in diethyl ether and washed successively with dilute hydrochloric acid solution, water and brine. After drying over magnesium sulfate, the diethyl ether was evaporated under vacuum to afford a yellow oil from which [[3-(tert-butyldimethylsilanyloxy)propyl](4-methoxybenzenesulfonyl)-amino]cyclohexylacetic acid benzyl ester, a clear oil (13.67 grams, 79%), was isolated by flash chromatography on silica gel eluting with 10% ethyl acetate in hexane.
(C) To a solution of [[3-(tert-butyldimethylsilanyloxy)propyl](4-methoxybenzenesulfonyl)amino]cyclohexylacetic acid benzyl ester (13.67 grams, 23.2 mmol) in methylene chloride (60 mL) at room temperature was added boron trifluoride etherate (21 mL, 171 mmol). After 20 minutes, the reaction was quenched by addition of saturated ammonium chloride solution and subsequent addition of ethyl acetate and water. The organic phase was separated, washed with brine and dried over magnesium sulfate. Evaporation of the solvent under vacuum gave an oil from which cyclohexyl[(3-hydroxypropyl)(4-methoxy-benzenesulfonyl)amino]acetic acid benzyl ester, a clear oil (11.25 grams, 100%), was isolated by flash chromatography on silica gel eluting with 20% ethyl acetate in hexane and then 40% ethyl acetate in hexane.
(D) Cyclohexyl[(3-hydroxypropyl)(4-methoxybenzenesulfonyl)amino]acetic acid benzyl ester (45.8 grams, 96 mmol) and sodium periodate (92.6 grams, 433 mmol) were dissolved in a mixture of acetonitrile (345 mL), carbon tetrachloride (345 mL) and water (460 mL). While cooling in an ice bath, ruthenium trichloride monohydrate (4.4 grams, 21 mmol) was then added. The resulting mixture was mechanically stirred with ice bath cooling for 30 minutes. The bath was removed and stirring was continued at room temperature for 4 hours. The reaction mixture was diluted with ethyl acetate and filtered through diatomaceous earth. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with water and saturated brine. After drying over magnesium sulfate, the solvents were evaporated to give a dark oil from which 3-[(benzyloxycarbonylcyclohexylmethyl)(4-methoxybenzenesulfonyl)amino]propionic acid, a white foam (28.1 grams, 60%), was isolated by flash chromatography on silica gel eluting sequentially with chloroform and
1% methanol in chloroform.
AP/P/ 9 7 / 0 1 0 78
AP.-0 0 73 J
-23(Ε) To a solution of 3-[(benzyloxycarbonylcyclohexylmethyl)(4-methoxybenzenesulfonyl)-amino]propionic acid (1.57 grams, 3.21 mmol) in methylene chloride (45 mL) were added sequentially triethylamine (1.12 mL, 8.04 mmol), methylpiperidin-4-ylcarbamic acid tert-butyl ester (0.89 grams, 4.15 mmol) , and (benzotriazol-1 -yloxy)tris(dimethylamino)-phosphonium hexafluoroborate (1.56 grams, 3.53 mmol). The resulting mixture was stirred for 16 hours at room temperature and then diluted with methylene chloride. The solution was washed successively with 0.5 M hydrochloric acid solution, saturated sodium bicarbonate solution and brine. The solution was dried over magnesium sulfate and concentrated to yield an oil which was chromatographed on silica gel eluting with 50% ethyl acetate in hexane to afford [{3-[4-(tert-butoxycarbonylmethylamino)piperidin-1-yl]-3-oxopropyl}(4-methoxybenzen esulfonyl)amino]cyclohexylacetic acid benzyl ester as an oil (1.89 grams, 86%).
(F) To a solution of [{3-[4-(tert-butoxycarbonylmethylamino)piperidin-1-yl]3-oxopropyl}(4-methoxybenzenesulfonyl)amino]cyclohexylacetic acid benzylester(1.89 grams, 2.76 mmol) in ethanol (90 mL) was added 10% palladium on activated carbon (0.32 grams). The mixture was agitated under 3 atmospheres hydrogen in a Parr shaker for 2 hours. The catalyst was removed by filtration through nylon (pore size 0.45 pm) and the solvent was evaporated leaving [{3-[4-(tert-butoxycarbonylmethylamino)piperidin-1-yl]-3-oxo-propyl}(4-methoxybenzenesulfonyl)amino]cyclohexylacetic acid as a white foam (1.65 grams, 100%).
(G) To a solution of [{3-[4-(tert-butoxycarbonylmethylamino)piperidin-1-yl]3-oxopropyl}(4-methoxybenzenesulfonyl)amino]cyclohexyiacetic acid(1,65grams, 2.76 mmol) in methylene chloride (30 mL) were added sequentially O-benzylhydroxylamine hydrochloride (0.47 grams, 2.94 mmol), triethylamine (1.25 mL, 9.0 mmol) and (benzotriazol-1 -yloxy)tris(dimethylamino)phosphonium hexafluoroborate (1.36 grams, 3.07 mmol). The resulting mixture was stirred for 24 hours at room temperature and then concentrated in vacuo. The residue was taken up in ethyl acetate and washed successively with 0.5 M hydrochloric acid solution, water, saturated sodium bicarbonate solution and brine. The solution was dried over magnesium sulfate and concentrated to yield an oil which was chromatographed on silica gel eluting with 40% hexane in ethyl acetate to afford (1-{3-[(benzyloxycarbamoylcyclohexylmethyl)(4-methoxybenzenesulfonyl)amino]-propionyl}piperidin-4-yl)methylcarbamic acid tert-butyl esteras a clear oil (1.86 grams, 96%).
AP/P/ 9 7 / 0 1 0 78
AP. Ο Ο 7 3 3
-24(H) To a solution of (1-{3-[(benzyloxycarbamoylcyclohexylmethyl)(4-methoxybenzenesulfonyl)amino]propionyl}piperidin-4-yl)methylcarbamic acid tert-butyl ester (1.86 grams, 2.65 mmol) in methanol (80 mL) was added 5% palladium on barium sulfate (0.85 grams). The mixture was agitated under 3 atmospheres hydrogen in a
Parr shaker for 2.5 hours. The catalyst was removed by filtration through nylon (pore size 0.45 pm) and the solvent was evaporated leaving (1-{3-[(cyclohexylhydroxycarbamoylmethyl)(4-methoxybenzene-sulfonyl)amino]propio nyl}piperidin-4-yl)methylcarbamic acid tert-butyl esteras a white foam (1.53 grams, 95%).
The title compounds of examples 2-8 were prepared analogously to that described in Example 1 using D-valine benzyl ester as the starting material in step A and the indicated amine in step E.
EXAMPLE 2
Acetic acid 1 -hvdroxycarbamovl-2-methvlpropvl)(4-methoxybenzenesulfonyl)-amino1propionvl)piperidin-4-vl ester Coupled with acetic acid piperidin-4-yl ester. MS: 500 (M+1).
EXAMPLE 3
Butyric acid 1-(3-Π1-hvdroxvcarbamovl-2-methyipropyi)-(4methoxv-benzenesulfonvl)-amino1propionyl)piperidin-4-vl ester
Coupled with butyric acid piperidin-4-yl ester. MS: 528 (M+1).
EXAMPLE 4
Benzoic acid 1-{3-H1-hvdroxvcarbamovi-2-methvlpropvlK4-methoxv-benzene25 sulfonvl)amino1propionyl)piperidin-4-vl ester
Coupled with benzoic acid piperidin-4-yl ester. MS: 562 (M+1). Analysis Calculated for C27H35N3O8S*1.75 H2O: C, 54.67; H, 6.54; N, 7.08. Found: C, 54.52, H, 6.14; N, 7.85.
Example 5
N-Hvdroxv-2-rr3-(4-hvdroxvpiperidin-1-vl)-3-oxopropvn-(4-methoxy-benzenesulfonvl)amino1-3-methylbutvramide
Coupled with 4-hydroxypiperidine. MS: 458 (M+1). Analysis calculated for C20H31N3O7S*H2O: C, 50.51; H, 6.99; N, 8.84. Found: C, 50.04; H, 6.84; N, 9.14.
AP/P/ 9 7 / 0 1 0 78
AP.00733
-25EXAMPLE 6 (1-<3-ni-Hvdroxvcarbamovl-2-methylpropvl)(4-methoxvbenzenesulfonvn-amino1
-propionvl)piperidin-4-vl)-methylcarbamic acid tert-butyl ester
Coupled with methyl-piperidin-4-ylcarbamic acid tert-butyl ester.
EXAMPLE 7
1-(3-r(1-Hvdroxvcarbamovl-2-methvlpropylH4-methoxvbenzenesulfonvl)-amino1· propionvDpiperidine-4-carboxylic acid ethyl ester
Coupled with piperidine-4-carboxylic acid ethyl ester. MS: 513 (M+1).
EXAMPLE 8 (4-{3-r(1-Hvdroxvcarbamovl-2-methylpropvl)(4-nriethoxvbenzenesulfonvl)-amino1propionvOpiperazin-l-vD-acetic acid ethyl ester
Coupled with piperazin-1-ylacetic acid ethyl ester. HRMS calculated for C23H37N4O8S(M+1): 529.2332. Found: 529.2366.
The title compounds of Examples 9-10 were prepared analogously to that described in Example 1 using D-leucine benzyl ester as the starting material in step A and the indicated amine in step E.
EXAMPLE 9 (1-{3-rf1-Hydroxvcarbamovi-3-methylbutyl)(4-methoxvbenzenesulfonvl)-aminolpropionv0piperidin-4-vl)methylcarbamic acid tert-butyl ester
Coupled with methyl-piperidin-4-ylcarbamic acid tert-butyl ester. MS: 585 (M+1).
EXAMPLE 10
1-(3-Γ(1-Hydroxy carbamovl-3-methylbutvl)-(4-methoxvbenzenesulfonvl)-amino125 propionvl}piperidine-4-carboxylic acid ethyl ester
Coupled with piperidine-4-carboxylic acid ethyl ester. Melting pont 78-80°C. MS: 528 (M+1).
The title compounds of Examples 11-13 were prepared analogously to that described in Example 1 using D-norleucine benzyl ester as the starting material in step A and the indicated amine or alcohol in step E.
AP/P/ 9 7 / 0 1 0 78
AP . Ο Ο 7 3 3
-26EXAMPLE11 (1-i3-r(1-Hvdroxvcarbamovlpentvil(4-methoxvbenzenesulfonvl)amino1propionvDpiperidin-4-vl)methvlcarbamic acid tert-butyl ester Coupled with methyl-piperidin-4-ylcarbamic acid tert-butyl ester.
EXAMPLE 12
1-f3-i(1-Hvdroxvcarbamoylpentvl)(4-methoxvbenzenesulfonyl)amino1propionvnpiperidine-4-carboxylic acid ethyl ester
Coupled with piperidine-4-carboxylic acid ethyl ester. MS: 528 (M+1).
EXAMPLE 13
3-r(1-Hvdroxvcarbamovlpentvl)(4-methoxvbenzenesulfonvl)aminol-propionicacid indan-5-vl ester
Coupled with 5-indanol. MS: 505 (M+1).
The title compounds of Examples 14-15 were prepared analogously to that 15 described in Example 1 using D-tert-butylalanine benzyl ester as the starting material in step A and the indicated amine in step E.
EXAMPLE 14 (1-f3-r(1-Hvdroxvcarbamovl-3.3-dimethvlbutvl)-(4-methoxvbenzene-sulfonvD20 aminolpropionvl)piperidin-4-vl)methylcarbamic acid tert-butyl ester
Coupled with methyl-piperidin-4-ylcarbamic acid tert-butyl ester. MS: 599 (M+1).
EXAMPLE 15
1-{3-r(1-Hvdroxvcarbamovl-3.3-dimethylbutvl)(4-methoxv-benzenesulfonyl)aminolpropionyl}piperidine-4-carboxvlic acid ethyl ester 25 Coupled with piperidine-4-carboxylic acid ethyl ester. MS: 542 (M+1).
The title compounds of Examples 16-18 were prepared analogously to that described in Example 1 using D-cyclohexylglycine benzyl ester as the starting material in step A and the indicated amine or alcohol in step E.
AP/P/ 97 / 0 1 0 78
ΉΡ . 407 3 3
-27EXAMPLE 16
2- Cvclohexvl-N-hvdroxv-2-rr3-(4-hvdroxvpiperidin-1-yl)-3-oxopropvn-(4methoxy-benzenesulfonvDaminolacetamide
Coupled with 4-hydroxypiperidine. MS: 498 (M+1). Analysis calculated for 5 C23H35N3O7S*0.5H2O: C, 54.53; H, 7.16; N, 8.29. Found: C, 54.21; H, 6.98; N, 8.21.
EXAMPLE 17
1-f3-nCvciohexvlhvdroxvcarbamovlmethvl)(4-methoxvbenzenesulfonyl)-aminoT propionvl)piperidine-4-carboxvlic acid ethyi ester
Coupled with piperidine-4-carboxylic acid ethyl ester. MS: 554 (M+1). Analysis 10 calculated for C26H39N3O8S»0.5H2O: C, 55.59; H, 7.16; N, 7.47. Found: C, 55.53; H,
7.18; N, 7.57.
EXAMPLE 18
3- f(Cvclohexvlhvdroxvcarbamovlmethvl)-(4-methoxvbenzenesulfonvl)-amino1propionic acid indan-5-vl ester
Coupled with 5-indanol. MS: 531 (M+1). Analysis calculated for C27H34N2O7S*H2O: C, 59.11; H, 6.61; N, 5.10. Found: C, 59.40; H, 6.17; N, 5.06.
The title compounds of Examples 19-20 were prepared analogously to that described in Example 1 using D-phenylalanine benzyl ester as the starting material in step A and the indicated amine in step E.
EXAMPLE 19 (l-f3-f(l-Hvdroxvcarbamovl-2-Dhenvlethvl)(4-methoxvbenzenesuIfonvl)-amino1propionvl)piperidin-4-vl)methvlcarbamic acid tert-butyl ester 25 Coupled with methyl-piperidin-4-ylcarbamic acid tert-butyl ester. MS: 619 (M+1).
EXAMPLE 20 l-(3-Kl-Hvdroxvcarbamovl-2-phenvlethvl)-(4-methoxvbenzenesulfonvl)-aminoL· propionvnpiperidine-4-carboxvlic acid ethyl ester
Coupled with piperidine-4-carboxylic acid ethyl ester. MS: 561 (M+1).
AP/P/ 9 7 / 0 1 0 78
AP.0 0 733
-28The title compounds of Examples 21-22 were prepared analogously to that described in Example 1 using D-4-fluorophenylalanine benzyl ester as the starting material in step A and the indicated amine in step E.
EXAMPLE 21 (l-f3-[f2-(4-Fluorophenvl)-l-hvdroxvcarbamovlethvn-(4-methoxv-benzenesulfonvl)aminolpropionyl)piperidin-4-yl)methylcarbamic acid tert-butyl ester
Coupled with methyI-piperidin-4-ylcarbamic acid tert-butyl ester.
EXAMPLE 22 l-{3-if2-(4-FluoronhenvO-l-hydroxycarbamoylethvll(4-methoxy-benzenesulfonvD aminolpropionvllpiperidine-4-carboxyIic acid ethyl ester
Coupled with piperidine-4-carboxylic acid ethyl ester. MS: 580 (M+l). Analysis calculated for C27H34FN3O8S: C, 55.95; H, 5.91; N, 7.25. Found: C, 55.72; H, 5.79; N, 7.08.
The title compounds of Examples 23-24 were prepared analogously to that described in Example 1 using D-4-homophenylalanine benzyl ester as the starting material in step A and the indicated amine in step E.
EXAMPLE 23 (l-i3-Kl-Hvdroxvcarbamoyl-3-phenvlpropvl)-(4-methoxvbenzene-sulfonyl)aminolpropionyl) niperidin-4-vI)methylcarbamic acid tert-butyl ester Coupled with tert-butyl ester using methyI-piperidin-4-ylcarbamic acid tert-butyl ester. MS: 633 (M+l).
EXAMPLE 24 l-(3-f(l-HvdroxvcarbamovI-3-phenylpropvh-(4-methoxvbenzene-sulfonvl)aminolpropionyllpiperidine-4-carboxylic acid ethyl ester
AP/P/ 97 / 0 1 0 78
Coupled with piperidine-4-carboxyIic acid ethyl ester. MS: 576 (M+l).
AP.00733
-29The title compounds of Examples 27-28 were prepared analogously to that described in Example 1 using D-O-tert-butylserine benzyl ester as the starting material in step A and the indicated amine in step E.
EXAMPLE 25 (l-(3-f(2-tert-Butoxv-l-hydroxvcarbamoylethvl)(4-methoxybenzene-sulfonvl)aminolpropionvl)piperidin-4-vI)methvlcarbamic acid tert-butyl ester Coupled with methyl-piperidin-4-ylcarbamic acid tert-butyl ester. MS: 615 (M+l).
EXAMPLE 26 l-(3-[(2-tert-Butoxv-l-hvdroxvcarbamovlethvl)(4-methoxy-benzenesiilfonvDaminolpropionvllpiperidine-4-carboxylic acid ethyl ester Coupled with piperidine-4-carboxyIic acid ethyl ester. MS: 558 (M+l).
The title compounds of Examples 27-28 were prepared analogously to that 15 described in Example 1 using D-cyclohexylalanine benzyl ester as the starting material in step A and the indicated amine in step E.
EXAMPLE 27 (l-(3-[(2-Cvclohexvl-l-hvdroxycarbamoylethyl)-(4-methoxv-benzene-sulfonvI)20 aminolpropionvl)piperidin-4-vl)methvlcarbamic acid tert-butyl ester
Coupled with methyl-piperidin-4-ylcarbamic acid tert-butyl ester. MS: 625 (M+l).
EXAMPLE 28 l-(3-[(2-Cyclohexvl-l-hvdroxycarbamovlethvl)(4-methoxv-benzenesulfonvBaminolnropionvllpiperidine-4-carboxylic acid ethyl ester 25 Coupled with piperidine-4-carboxylic acid ethyl ester. MS: 568 (M+l).
The title compounds of Examples 29-30 were prepared analogously to that described in Example 1 using D-l-naphthylalanine benzyl ester as the starting material in step A and the indicated amine in step E.
AP/P/ 97 / 0 1 0 78
AP.00733
-30EXAMPLE 29 (l-f3-[(l-Hvdroxvcarbamoyl-2-naphthalen-l-vlethvD-(4-methoxv-benzenesulfonvl)aminolpropionvllniperidin-4-yr)methvlcarbamic acid tert-butyl ester
Coupled with methyIpiperidin-4-yIcarbamic acid tert-butyl ester.
EXAMPLE 30
1- (3-f(l-Hvdroxvcarbamoyl-2-naphthalen-l-ylethyl)(4-methoxvbenzene-sulfonvD aminolpropionvnpiperidine-4-carboxvlic acidethyl ester Coupled with piperidine-4-carboxylic acid ethyl ester. MS: 611 (M+l).
EXAMPLE 31
2-Cvclohexyl-N-hvdroxv-2-{(4-methoxvbenzenesulfonyl)-f3-(4-methyI-aminopiperidin-l-vl)-3-oxopropyl]-amino)acetamide
A solution of l-{3-[(cyclohexylhydroxycarbamoylmethyl)(4-methoxybenzenesulfonyl)-amino]-propionyl }piperidin-4-yl)methylcarbamic acid tert-butyl ester (1.53 grams, 2.50 mmol) in methylene chloride (70 mL) was bubbled with hydrochloric acid gas for 2 minutes. The ice bath was removed and the reaction mixture was allowed to stir at room temperature for 1 hour. The solvent was evaporated and twice methanol was added to the residue and evaporated leaving
2- cyclohexyl-N-hydroxy-2-{(4-methoxybenzenesulfonyl)-[3-(4-methylaminopiperidinl-yl)-3-oxopropyl]-amino}acetamide hydrochloride dihydrate as a white solid (1.22 grams, 90%). MS: 511 (M+l). Analysis calculated for C24H39C1N4O6S*2H2O: C, 49.43; H, 7.43; N, 9.61. Found: C, 49.86; H, 7.23; N, 9.69.
The title compounds of Examples 32-41 were prepared analogously to that described in Example 33 using the starting material indicated.
EXAMPLE 32
N-Hvdroxv-2-((4-methoxvbenzenesulfonvDf3-(4-methvIaminopiperidin-l-vr)-3oxopropvllamino)-3-methvlbutvramide hydrochloride
Starting material: (1 - {3 - [(1 -hydroxycarbamoyl-2-methylpropyl)(4-methoxybenzene30 sulfonyl)-amino]propionyl}piperidin-4-yl)-methylcarbamic acid tert-butyl ester using methyl-piperidin-4-ylcarbamic acid tert-butyl. MS: 471 (M+l).
AP/P/ 9 7 / 0 1 0 78
AP.0 073 J
-31EXAMPLE 33
2-{(4-MethoxvbenzenesuIfonvl)-f3-(4-methylaminopiperidin-l-vl)-3-oxo-propyUamino)4-methylpentanoic acid hvdroxyamide hydrochloride
Starting material: (1 - {3- [(1 -hydroxycarbamoy l-3-methylbutyl)(4-methoxybenzene5 sulfonyl)amino]propionyl}piperidin-4-yl)methylcarbamic acid tert-butyl ester.
Melting Point 170-173°C. MS: 485 (M+l).
EXAMPLE 34
2- ((4-Methoxvbenzenesulfonvl)-f3-(4-methvlaminopiperidin-l-vl)-3-oxo-propyll aminolhexanoic acid hvdroxyamide hydrochloride 10 Starting material: (l-{3-[(l-hydroxycarbamoylpentyl)-(4-methoxybenzenesulfonyl)amino]-propionyl}piperidin-4-yl)methyl-carbamic acid tert-butyl ester. MS: 485 (M+l). Analysis calculated for C2,H34N4O6S*HC1*4H2O: C, 43.5; H, 7.48; N, 9.67. Found: C, 43.65; H, 7.03; N, 9.79.
EXAMPLE 35
2-((4-Methoxvbenzenesulfonvl)-f3-(4-methvlaminopiperidin-l-vI)-3-oxo-propyll aminol-4,4-dimethyInentanoic acid hvdroxyamide hydrochloride Starting material: (1 -{3-[( 1 -hydroxy-carbamoyl-3,3-dimethylbutyl)(4-methoxybenzenesulfonyl)amino]propionyl}piperidin-4-yl)methylcarbamic acid tert-butyl ester. MS: 499 (M+l).
EXAMPLE 36
N-Hvdroxv-2-f(4-methoxybenzenesulfonvl)-i3-f4-methylaminopiperidin-l-yl)-3oxopropyllamino)-3-phenvlpropionamide hydrochloride
Starting material: (1 - {3 - [(1 -hydroxycarbamoy l-2-phenylethyl)(4-methoxybenzenesulfonyl)-amino]propionyl}piperidin-4-yI)methylcarbamic acid tert-butyl ester.
MS: 519 (M+l).
EXAMPLE 37
3- (4.Fluorophenvl)-N-hvdroxy-2-((4-methoxvbenzenesulfonvl)-f3-(4-methylamino piperidin-l-vl)-3-oxo-nropyIlamino)propionamide hydrochloride
Starting material: (1 -{3-[[2-(4-fluorophenyl)-l-hydroxycarbamoylethyl]-(4-methoxy30 benzenesulfonyl)amino]propionyl}-piperidin-4-yl)methylcarbamic acid tert-butyl ester
AP/P/ 9 7 / 0 1 0 78
AP.0073J
-32(Example 21). MS: 537 (M+l). Analysis calculated for C25H33FN4O6S»HC1»2H2O: C, 49.30; H, 6.29; N, 9.20. Found: C, 49.14; H, 5.82; N, 9.24.
EXAMPLE 38
N-Hvdroxv-2-f(4-methoxvbenzenesulfonvi)-f3-(4-methylaminopiperidin-l-yl)-35 oxopropvllaminol-4-phenvlbutyramide hydrochloride
Starting material: (1 - {3 - [(1 -hydroxycarbamoyl-3 -phenylpropyl)(4-methoxybenzenesulfonyl)amino] propionyl }piperidin-4-yl)methylcarbamic acid tert-butyl ester. Melting Point 160-170°C. MS: 533 (M+l). Analysis calculated for C26H36N4O6S*HC1*1.5H2O: C, 52.38; H, 6.76; N, 9.40. Found: C, 52.25; H, 6.40;
N, 9.00.
EXAMPLE 39
3-tert-Butoxv-N-hvdroxv-2-f(4-methoxvbenzenesulfonvl)-i3-(4-methyl-aminopiperidin-l-vl)-3-oxopropvIl-amino)propionamide hydrochloride Starting material: (1 -{3-[(2-tert-butoxy-l-hydroxycarbamoylethyl)(4-methoxy15 benzenesulfonyl)amino]propionyl}piperidin-4-yl)methylcarbamic acid tert-butyl ester. MS: 515 (M+l).
EXAMPLE 40
3-Cvclohexyl-N-hvdroxy-2-{(4-methoxvbenzenesuIfonvl)-f3-(4-methyl-aminopiperidin-l-vD-3-oxopropyllamino)propionamide hydrochloride
Starting material: (l-{3-[(2-cyclohexyl-l-hydroxycarbamoylethyl)-(4-methoxybenzenesulfonyl)amino]propionyl}piperidin-4-yl)methylcarbamic acid tert-butyl ester. MS: 525 (M+l).
EXAMPLE 41
N-Hvdroxy-2-((4-methoxybenzenesulfonyl)-[3-(4-methylaminopiperidin-l-vl)-325 oxopropyllaminol-3-naphthalen-l-ylpropionamide hydrochloride
Starting material: (1 -{3-[( 1 -hydroxy-carbamoyl-2-naphthalen-1 -ylethyl)-(4-methoxybenzenesulfonyl)amino]propionyl} -piperidin-4-yl)methylcarbamic acid tert-butyl ester. MS: 569 (M+l).
AP/P/ 9 7 / 0 1 0 78
AP. (ΤΟ 7 3 3
-33EXAMPLE 42 l-(3-K'Cvclohexvlhvdroxvcarbamovlmethyl)-(4-methoxvbenzenesulfonyI)-aminolpropionvl)piperidine-4-carboxylic acid
To a solution of l-{3-[(cyclohexylhydroxycarbamoylmethyl)(4-methoxy- .
benzenesulfonyl)amino]propionyl}piperidine-4-carboxylic acid ethyl ester (0.62 grams, 1.16 mmol) (Example 17) in ethanol (45 mL) and water (5 mL) was added lithium hydroxide monohydrate (0.24 grams, 5.72 mmol). After stirring for 3 hours at room temperature ethanol-washed Amberlite IR-120 plus ion exchange resin (6 grams) was added. Stirring was continued for 15 minutes and then the mixture was filtered. The filtrate was concentrated in vacuo to give l-{3-[(cyclohexylhydroxycarbamoylmethyl)-(4-methoxy-benzenesulfonyl)amino]propi onyl}-piperidine-4-carboxylic acid monohydrate as a white solid (0.52 grams, 88%). MS: 526 (M+l). Analysis calculated for CMH35N3O,S*H2O: C, 53.03; H, 6.86; N, 7.73. Found: C, 53.53; H, 7.15; N, 7.70.
The title compounds of Examples 43-53 were prepared analogously to that described in Example 45 using the starting material indicated.
EXAMPLE 43 l-{3-ftl-Hvdroxvcarbamovl-2-methvlpropyl)(4-methoxvbenzene-sulfonyl)aminol propionyl)piperidine-4-carboxvlic acid
Starting material: 1 - {3 - [(1 -hydroxycarbamoyl-2-methylpropyl)(4-methoxybenzenesulfonyl)amino]propionyl}piperidine-4-carboxylic acid ethyl ester. MS: 486 (M+l).
EXAMPLE 44 (4-f3-ftl-HvdroxvcarbamovI-2-methvlpropvl)(4-methoxvbenzene-sulfonvl)amino1 propionyl) niperazin-l-vl)acetic acid
Starting material: (4-{3-[(1 -hydroxycarbamoyl-2-methylpropyl)(4-methoxybenzenesulfonyl)amino]-propionyl}piperazin-l-yl)acetic acid ethyl ester (Example 8). MS: 500 (M+l).
AP/P/ 9 7 / 0 1 0 78
AP . Ο Ο 7 3 3
-34EXAMPLE 45 l-{3-f(l-Hvdroxvcarbamovl-3-methvlbutvl)-(4-methoxvbenzenesulfonyl)-aminolpropionvnpiperidine-4-carboxvlic acid
Starting material: 1 - {3 - [(1 -hydroxycarbamoyl-3-methylbutyl)(4-methoxybenzene5 sulfonyl)-amino]propionyl}piperidine-4-carboxylic acid ethyl ester. Melting Point 118120°C. MS: 500 (M+l).
EXAMPLE 46 l-i3-i(l-Hvdroxvcarbamovlpentvl)(4-methoxvbenzenesulfonvl)aminol-propionvn piperidine-4-carboxvlic acid
Starting material: 1-{3-((1-hydroxycarbamoylpentyl)(4-methoxybenzenesulfonyl)amino]propionyl}piperidine-4-carboxylic acid ethyl ester. MS: 500 (M+l).
EXAMPLE 47 l-f3-f(l-Hvdroxvcarbamoyl-3,3-dimethvlbutvl)(4-methoxv-benzene-suIfonvl)aminolpropionvHniperidine-4-carboxvlic acid 15 Starting material: I-{3-((1 -hydroxycarbamoyl-3,3-dimethylbutyl)(4-methoxybenzenesulfonyl)-amino]propionyl}piperidine-4-carboxylic acid ethyl ester. MS: 514 (M+l). EXAMPLE 48 l-{3-f(l-Hvdroxvcarbamovl-2-phenvlethvI)-(4-methoxybenzenesulfonyl)-aminolpropionvnpiperidine-4-carboxvlic acid
Starting material: 1 - {3 - [(1 -hydroxycarbamoyl-2-phenyl-ethy l)(4-methoxybenzenesulfonyl)-amino]propionyl}piperidine-4-carboxylic acid ethyl ester. MS: 534 (M+l).
EXAMPLE 49 l-(3-H2-(4-Fluorophenvl)-l-hvdroxvcarbamovlethvll(4-methoxvbenzene-sulfonvl) aminolpropionyI|piperidine-4-carboxvlic acid 25 Starting material: l-{3-([2-(4-fluorophenyl)-l-hydroxycarbamoylethyl](4-methoxybenzenesulfonyl)amino]propionyl}piperidine-4-carboxylic acid ethyl ester.
MS: 552 (M+l). Analysis calculated form C25H3oFN3O8S*0.5H2O: C, 53.56; H, 5.57; N, 7.50. Found: C, 53.53; H, 5.39; N, 7.28.
AP/P/ 9 7 / 0 1 0 78
AP . Ο Ο 7 3 3
-35EXAMPLE 50
- (3- f(l-Hvdroxyearbamovl-3-phenvlpropyI)(4-methoxybenzenesuIfonvI)-aminolpropionyl)piperidine-4-carboxylic acid
Starting material: 1 - {3 - [(1 -hydroxycarbamoyl-3 -phenyl-propyl)-(4-methoxybenzene5 sulfonyl)-amino]propionyl}piperidine-4-carboxylic acid ethyl ester. Melting Point 8592°C. MS: 598 (M+l).
EXAMPLE 51 l-(3-f(2-tert-Butoxv-l-hvdroxvcarbamoylethvI)f4-methoxvbenzene-sulfonvl)amino1nropionvl)pineridine-4-carboxvIic acid
Starting material: l-{3-[(2-tert-butoxy-l-hydroxycarbamoylethyl)(4-methoxybenzenesulfonyl)-amino]propionyl}piperidine-4-carboxylic acid ethyl ester.
MS: 529 (M+l).
EXAMPLE 52 l-{3-l(2-CvcIohexvl-l-hvdroxycarbamovIethvl)(4-methoxvbenzene-sulfonvl)15 aminol propionyl) piperidine-4-carboxyIic acid
Starting material: 1 - {3 - [(2-cyclohexy 1-1 -hydroxycarbamoy lethy l)(4-methoxybenzenesulfonyl)amino]propionyl}piperidine-4-carboxylic acid ethyl ester.
MS: 540 (M+l).
EXAMPLE 53 l-i3-f(l-Hvdroxvcarbamovl-2-naphthalen-l-ylethvI)(4-methoxvbenzene-sulfonyl) aminolpropionyl)piperidine-4-carboxylic acid
Starting material: 1 - {3-[( 1 -hydroxycarbamoyl-2-naphthalen-1 -ylethyl)(4-methoxybenzenesulfonyl)amino]propionyl}piperidine-4-carboxylic acidethyl ester.
MS: 584 (M+l).
EXAMPLE 54
N-Hvdroxv-2-H3-14-(2-hvdroxvethvDpiperazin-l-yll-3-oxopropyl)-(4-methoxvben zenesulfonvDaminol-3-methylbutvramide (A) To a solution of 2-[(2-carboxyethyl)-(4-methoxybenzenesulfonyl)amino]-3methylbutyric acid benzyl ester(prepared staring from D-valine benzyl ester according to the procedure of Example 1, steps A to D) (1.35 grams, 3.0 mmol) in methylene chloride (45 mL) were added sequentially triethylamine (0.92 mL, 6.9 mmol),
AP/P/ 97/01078
AP .0-0 7 3 3
-362-piperazin-l-ylethanol (0.43 grams, 3.3 mmol) and (benzotriazol-l-yloxy)tris(dimethylamino)-phosphonium hexafluoroborate (1.53 grams, 3.45 mmol). The resulting mixture was stirred for 16 hours at room temperature and then concentrated in vacuo. The residue was taken up in ethyl acetate and washed with saturated sodium bicarbonate solution and brine. The solution was dried over magnesium sulfate and concentrated to yield an oil which was chromatographed on silica gel eluting with 5% methanol in chloroform to afford 2-[{3-[4-(2-hydroxyethyl)piperazin-l-yl]-3-oxopropyl}(4-methoxybenzenesulfonyl)amino]-3-methy lbutyric acid benzyl esteras an oil (1.40 grams, 83%). Conversion to the hydrochloride salt was subsequently carried out using anhydrous hydrochloric acid in cold (O’C) methylene chloride.
(B) To a solution of 2-[{3-[4-(2-hydroxyethyl)piperazin-l-yl]-3-oxopropyl}(4-methoxy-benzenesulfonyl)amino]-3-methylbutyric acid benzyl ester hydrochloride (1.49 grams, 2.49 mmol) in ethanol (80 mL) was added 10% palladium on activated carbon (0.11 grams). The mixture was agitated under 3 atmospheres hydrogen in a Parr shaker for 16 hours. The catalyst was removed by filtration through nylon (pore size 0.45 μια) and the solvent was evaporated leaving 2-[{3-[4-(2-hydroxyethyl)piperazinl-yl]-3-oxo-propyl}(4-methoxybenzenesulfonyl)amino]-3-methylbutyric acid hydrochloride as a white solid (1.16 grams, 92%).
(C) To a solution of 2-[{3-[4-(2-hydroxyethyl)piperazin-l-yl]-3-oxo20 propyl}(4-methoxy-benzenesuifonyl)amino]-3-methylbutyric acid hydrochloride (1.10 grams, 2.17 mmol) in methylene chloride (50 mL) and Ν,Ν-dimethylformamide (0.5 mL) were added sequentially O-benzylhydroxylamine hydrochloride (0.41 grams, 2.60 mmol), triethylamine (0.91 mL, 6.5 mmol) and (benzotriazol-l-yloxy)tris(dimethylamino)-phosphonium hexafluoroborate (1.20 grams, 2.71 mmol). The resulting mixture was stirred for 16 hours at room temperature and then concentrated in vacuo. The residue was taken up in ethyl acetate and washed successively with saturated sodium bicarbonate solution, water and brine. The solution was dried over magnesium sulfate and concentrated to yield an oil which was chromatographed on silica gel eluting with 3% methanol in chloroform to afford N-benzyloxy30 2-[{3 - [4-(2-hy droxy ethy l)piperazin-1 -y 1] -3 -oxopropyl} (4-methoxybenzenesulfony l)am ino]-3-methylbutyramide as a clear oil (0.85 grams, 68%). Conversion to the
AP/P/ 9 7 0 1 0 7 8
AP . Ο Ο 7 3 3
-37hydrochloride salt was subsequently carried out using anhydrous hydrochloric acid in cold (0*C) methylene chloride.
(D) To a solution of N-benzyloxy-2-[{3-[4-(2-hydroxyethyl)piperazin-l-yl]3-oxopropyl}-(4-methoxybenzenesulfonyl)amino]-3-methylbutyramide hydrochloride (0.39 grams, 0.63 mmol) in methanol (30 mL) was added 5% palladium on barium sulfate (0.19 grams). The mixture was agitated under 3 atmospheres hydrogen in a Parr shaker for 2.25 hours. The catalyst was removed by filtration through nylon (pore size 0.45 μτη) and the solvent was evaporated to a tan foam which was chromatographed on silica gel eluting with 15% methanol in chloroform containing 0.5% ammonium hydroxide. Clean fractions containing the desired product were taken up in saturated sodium bicarbonate solution. The resulting mixture was extracted several times with ethyl acetate and the combined extracts were concentrated to afford N-hy droxy-2-[ {3 - [4-(2-hydroxyethyl)piperazin-1 -yl]-3-oxopropyl} -(4-methoxybenzen esulfonyl)amino]-3-methyl-butyramide as an oil. The hydrochloride salt (0.20 grams,
61%) was formed using anhydrous hydrochloric acid in cold (0°C) methanol. MS: 487 (M+l). Analysis calculated for C2,H34N4O7S*HCl*0.5H2O: C, 47.41; H, 6.82; N, 10.53. Found: C, 47.41; H, 7.11; N, 9.91.
The title compounds of Examples 55-57 were prepared analogously to that described in Example 58 using the indicated amine in step A.
EXAMPLE 55
2-H3-(4-Dimethvlaminopiperidin-l-vD-3-oxopropvlI(4-methoxvbenzene-sulfonvD aminol-N-hydroxy-3-methvlbutvramide
Coupled with dimethylpiperidin-4-ylamine. MS: 485 (M+l).
EXAMPLE 56
N-Hvdroxv-2-[{3-f4-(3-hvdroxvpropvDpiperazin-l-vn-3-oxopropvn-(4-methoxvbenzenesuIfonvl)amino]-3-methvlbutyramide
AP/P/ 9 7.0 1 0 78
Coupled with 3-piperazin-l-ylpropan-l-ol. MS: 500 (M+l).
AP . Ο Ο 7 3 3
-38EXAMPLE 57
2-K3-ri.4’lBipiperidmvl-r-yl-3-oxopropyl)-(4-inethoxvbenzenesulfonyI)-aniinol-Nhydroxy-3-methvIbutyraTnide
Coupled with using [l,4’]bipiperidinyl. MS: 525 (M+l). Analysis calculated for 5 C25H40N4O6S*HCl»1.5H2O: C, 51.05; H, 7.54; N, 9.52. Found: C, 50.80; H, 7.45;
N, 9.36.
EXAMPLE 58 l-{3-r(l-Hydroxycarbamoyl-2-methvlpropyl)-(4-phenoxybenzenesulfonvl) aminol propionyl! piperidine-4-carboxylic acid ethyl ester 10 The title compound was prepared analogously to that described in Example 1 using D-valine benzyl ester and 4-phenoxybenzenesulfonyl chloride as the starting materials in step A and piperidine-4-carboxylic acid ethyl ester in step E. Analysis calculated for C28H37N3O8S. O.1CH2C12: C, 57.78; H, 6.42; N, 7.19. Found: C, 57.46; H, 6.41; N, 7.11.
EXAMPLE 59 l-f3-i(l-HvdroxvcarbamovI-2-methvIpropvl)-(4-phenoxvbenzenesulfonvl) aminol propionyl! piperidine-4-carboxvlic acid
The title compound was prepared analogously to that described in Example 42 using l-{3-[(l-hydroxycarbamoyl-2-methylpropyl)-(4-phenoxybenzenesulfonyl)amino] 20 propionyl]piperidine-4-carboxylic acid ethyl ester (Example 58) as the starting material.
MS: 548 (M+l). Analysis calculated for C26H33N3O8S. 0.5H2O: C, 56.10; H, 6.16; N, 7.75. Found: C, 55.99; H, 6.06; N, 7.43.

Claims (11)

  1. A compound of the formula
    Having now particularly described and ascertained my/our said invention and <n v, ha: manner the same is to be performed I/we declare that what I/we claim is —
    H0-NI
    H
    II
    -C, <CH2)n
    R3 |
    C-N
    R4 \ o \// s\ o a or the pharmaceutically acceptable salts thereof, wherein n is 1 to 6;
    X is OR1 wherein R1 is as defined below; azetidinyl, pyrrolidinyl, piperidinyl, morpholinyi, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl,
    15 tetrahydroisoquinolinyl, piperazinyl or a bridged diazabicycloalkyl ring selected from the group consisting of
    AP/P/ 9 7 0 1 0 7 8 a
    AiP . 0 0 7 3 3
    N :n (CH2)r wherein r is 1, 2 or 3; m is 1 or 2; and p is 0 or 1;
    wherein each heterocyclic group may optionally be substituted by one or two groups selected from hydroxy, (Ci-C6)alkyl, (Ci-C6)alkoxy, (Cj-Cjojacyl, (C1-C10)acyloxy, (C6C10)aryl, (C5-C9)heteroaryl, (C6-C10)aryl(Cj-C6)alkyl, (C5-C9)heteroaryl (CrC^alkyl, hydroxy (C,-C6)alkyl, (CrC6)alkoxy (C,-C6)alkyl, (C.-QacyloxyiCj-CJalkyl, (Cr C6)alkylthio, (Cj-C6)alkylthio (Cj-Cejalkyl, (C6-Ci0)arylthio, (C6-C10) arylthioCCjC6)alkyl, R9RI0N, R9R10NSO2, R9R10NCO, R9R10NCO(C,-C6)alkyl wherein R9 and R10 are each independently hydrogen, (Cj-C^alkyl, (C6-C10)aryl, (C5-C9)heteroaryl, (C6Cio)aryl (Cj-CJalkyl or (C5-C9)heteroaryl (CrCJalkyl or R9 and R10 may be taken together with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or thiomorpolinyl ring; R12SO2, R12SO2NH wherein R12 is trifluoromethyl, (Q-CJalkyl, (C6-C10)aryl, (C5-C9)heteroaryl, (C6C10)aryl(C,-C6)alkyl or (C5-C9)heteroaryl (Cj-C6)alkyl; R13CONR9 wherein R9 is as defined above and R13 is hydrogen, (Cj-C6)alkyl, (C2-C6)alkoxy, (C0-C10)aryl, (C5C9)heteroaryl, (C1-C6)aryl(C1-C6)alkyl(C6-C10)aryl(Ci-C6)alkoxy or (Cs-C^heteroaryXCjC6)alkyl; R14OOC, R14OOC(C1-C6)alkyl wherein R14 is (Cj-C6)alkyl, (C6-C10)aryl, (C5C9)heteroaryl, (C6-C10)aryl (Cj-C6)alkyl, 5-indanyl, CHR5OCOR6 wherein R5 is hydrogen or (Cj-CJalkyl and R6 is (Cj-C6)alkyl, (C2-C6)alkoxy or (C6-C10)aryl; CH2CONR7R8 wherein R7 and R8 are each independently hydrogen or (Ci-C6)alkyl or may be taken together with the nitrogen to which they are attached to form an
    AP/P/9 7. ύ 1 0 78
    AP.ύ Ο 7 3 3
    -41azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or thiomorpholinyl ring; or R15O (CjC^alkyl wherein R15 is H2N(CHR16)CO wherein R16 is the side chain of a natural D- or L-amino acid;
    R1 is (C6-C10)aryl, (C5-C9)heteroaryl, (C^CjojaryKCj-CeJalkyl, 5-indariyl,
    5 CHR5OCOR6 or CH2CONR7R8 wherein R5, R6, R7 and R8 are as defined above;
    R3 and R4 are each independently selected from the group consisting of hydrogen, (Ci-C6)alkyl, trifluoromethyi, trifluoromethyl(Ci-C6)alkyl, (C,-C6)alkyl (difluoromethylene), (C1-C3)alkyl(difluoromethylene)(C1-C3)alkyl, (C6-CJ0)aryl, (C5C9)heteroaryl, (Cg-C^jaryhCj-C^alkyi, (Cj-CcOheteroaryliCj-Cgjalkyl, (C6-C10)aryl(C610 CI0)aryl, (C6-C10)aryl(C6-C10)aryl(C1-C6)alkyl, (C3-C6)cycloalkyl, (Cj-CgjcycloalkyKCr C6)alkvl,hydroxy(C1-C6)alkyl,(C1-C10)acyloxy(C1-C6)alkyl,(C1-C6)alkoxy(C1-C6)alkyl, (C,-Ci0)acylamino(C,-C6)alkyl, piperidyl, (C,-C6)alkylpiperidyl, (C0- C10)aryl(Cr C6)alkoxy(C1-C6)alkyl, (Q-C^heteroaryhCj-CJalkoxytCj-C^alkyl, (Cj-C^alkylthioiCjC6)alkyl, (C6-C10)arylthio(CrC6)alkyl, (C,-C6)alkylsulfinyl(C1-C6)alkyl, (C615 CjojarylsulfinyfrCj-CJalkyl, (Q-C^alkylsulfonyKCpCejalkyl, (C6-C10)arylsulfonyl(CIC6)alkyl, aminoCCpC^alkyl, (C1-C6)alkylamino(C1-C6)alkyl, ((Ci-C6)alkylamino)2(C1C6)alkyl, R17CO(C,-C6)alkyl wherein R17 is R14O or R7R8N wherein R7, R8 and R14 are as defined above; or R18(C,-C6)alkyl wherein R18 is piperazinyl, (C,C10)acylpiperazinyl, (C6-Ci0)arylpiperazinyl, (C5-C9)heteroarylpiperazinyl, (Cr
    20 C6)alkylpiperazinyl, (Ce-C^ary^Cj-CUalkylpiperazinyl, (Cs-CojheteroaryltCjC6)alkylpiperazinyl, morpholinyl, thiomorpholinyl, piperidinyl, pyrrolidinyl, piperidyl, (C]-C6)alkylpiperidyl, (C6-C10)arylpiperidyl, (C5-C9)heteroarylpiperidyl, (C6-C10)aryl(CiC6)alkylpiperidyl, (C5-C9)heteroaryl(Ci-C6)alkylpiperidyl or (Ci-C10)acylpiperidyl;
    or R3 and R4 may be taken together to form a (C3-C6)cycloalkyl, oxacyclohexyl,
    25 thiocyclohexyl, indanyl or tetralinyl ring or a group of the formula
    AP/P/ 9 7.01078
    N
    I
    R
    AP. ΰ Ο 7 3 3
    -42wherein R21 is hydrogen, (Cj-Cjojacyl, (CpC^alkyl, (C6-C10)aryl(C1-C6)alkyl, (C5CgjheteroaryfrCj-C^alkyl or (Ci-C6)alkylsulfonyl; and
    Q is (C,-C6)alkyl, (C6-C10)aryl, (C6-C10)aryloxy(C6-Ci0)aryl, (C6-C10)aryl(C6C10)aryl, (C6-C10)aryl(C6-C10)aryl(C1-C6)alkyl, (C6-C10)aryloxy(C5-C9)heteroaryl, (C5C9)heteroaryl, (C,-C6)alkyl(C6-C10)aryl, (Ci-C6)alkoxy(C6-C10)aryl, (C6-C10)aryl(Cr C6)alkoxy(C6-CI0)aryl,(C6-C10)aryl(C1-C6)alkoxy(C1-C6)alkyl,(C5-C9)heteroaryloxy(C6C10)aryl, (Cj-C^alkyKCj-Csjheteroaryl, (Ci-C6)alkoxy(C5-C9)heteroaryl, (C6C10)aryl(CrCJalkoxy(C5-C9)heteroaryl, (C5-C9)heteroaryloxy(C5-C9)heteroaryl, (C6CmjaryloxyCCj-CsJalkyl, (C5-C9)heteroaryloxy(CrC6)alkyl, (Cj-C^alky^CeCiojaryloxyiCs-C^iaryl/Cj-CejalkyKCs-C^heteroaryloxyiCe-Ciojaryl/Ci-CeialkylCCeC10)aryloxy(C5-C9)heteroaryl, (Cj-CJalkoxyiCe-C^aryloxyCCg-C^aryl, (Cr C6)alkoxy(C5-C9)heteroaryloxy(C6-C10)aryl or (C1-C6)alkoxy(C6-Ci0)aryloxy(C5C9)heteroaryl wherein each aryl group is optionally substituted by fluoro, chloro, bromo, (Ci-C6)alkyl, (Cj-C^alkoxy or perfluoro(Ci-C3)alkyl;
    with the proviso that X must be substituted when defined as azetidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, piperazinyl, (C1-C10)acylpiperazinyl, (CxC6)alkylpiperazinyl, (C6-C10)arylpiperazinyl, (C5-C9)heteroarylpiperazinyl or abridged diazabicycloalkyl ring.
  2. 2. A compound according to claim 1, wherein n is 2.
  3. 3. A compound according to claim 1, wherein either R3 or R4 is not hydrogen.
  4. 4. A compound according to claim 1, wherein Q is (C]-C6)alkoxy(C6C10)aryl, (Ce-C^jaryKCrCJalkoxyiCe-Cjoiaryl, phenoxy(C6-C10)aryl, 4fluorophenoxy(C6-C10)aryl, 4-fluorobenzyloxy(C6-C10)aryl or (C!-C6)alkyl(C6C10)aryloxy(C6-C10)aryl.
  5. 5. A compound according to claim 1, wherein X is indolinyl or piperidinyl.
  6. 6. A compound according to claim 1, wherein n is 2; either R3 or R4 is not hydrogen; Q is (C1-C6)alkoxy(C6-C10)aryl, (C6-C10)aryl(C1-C6)aIkoxy(C6-C10)aryl, 4fluorophenoxy(C6-Cio)aryl, phenoxy (C6-C10)aryl, 4-fluorobenzyloxy(C6-C10)aryl or (Cr C6)alkyl(C6-C10)aryloxy(C6-C10)aryl; and X is indolinyl or piperidinyl.
    AP/P/ 9
  7. 7 / 0 1 0 78
    AP . 0 Ο 7 3 3
    -437. A compound according to claim 1, wherein said compound is selected from the group consisting of:
    3-[(Cyclohexylhydroxycarbamoylmethyl)-(4-methoxybenzenesulfonyl)-amino]propionic acid indan-5-yl ester;
    5 Acetic acid l-{3-[(l-hydroxycarbamoyl-2-methylpropyl)-(4-methoxy-benzenesulfonyl)-amino]propionyl}piperidin-4-yl ester;
    2-Cyclohexyl-N-hydroxy-2-[[3-(4-hydroxypiperidin-l-yl)-3-oxopropyl]-(4-methoxy-benzenesulfonyl)amino]acetamide;
    Benzoicacidl-{3-[(l-hydroxycarbamoyl-2-methylpropyl)-(4-methoxy-benzene10 sulfonyl)amino]propionyl}piperidin-4-yl ester;
    N-Hydroxy-2-[[3-(4-hydroxypiperidin-l-yl)-3-oxopropyl]-(4-methoxybenzenesulfonyl)amino]-3-methylbutyramide;
    1- {3-[(Cyclohexylhydroxycarbamoylmethyl)-(4-methoxybenzenesulfonyl)-amino]propionyl}piperidine-4-carboxylic acid;
    15 1 -{3-[(Cyclohexylhydroxycarbamoylmethyl)-(4-methoxybenzenesulfonyl)amino]propionyl}piperidine-4-carboxylic acid ethyl ester;
    2- Cyclohexyl-N-hydroxy-2-{(4-methoxybenzenesulfonyl)-[3-(4-methylaminopiperidin-1 -yl)-3-oxopropyl]amino}acetamide;
    3- (4-Chlorophenyl)-N-hydroxy-2-{(4-methoxybenzenesulfonyl)20 [3-(4-methylaminopiperidin-l-yl)-3-oxopropyl]amino}propionamide;
    3-Cyclohexyl-N-hydroxy-2-{(4-methoxybenzenesulfonyl)-[3-(4-methylaminopiperidin-1 -yl)-3-oxopropyl]amino}propionamide;
    N-Hydroxy-2-[{3-[4-(2-hydroxy-2-methylpropyl)piperazin-l-yl]3-oxopropyl}-(4-methoxy-benzenesulfonyl)amino]-3-methylbutyramide;
    25 2,2-Dimethylpropionicacid2-(4-{3-[(l-hydroxycarbamoyl-2-methylpropyl)-(4methoxy-benzenesulfonyl)amino]propionyl}piperazin-l-yl)ethyl ester;
    Benzoic acid 2-(4-{3-(( l-hydroxycarbamoyl-2-methylpropyl)-(4-methoxybenzenesulfonyl)-amino]propionyl}piperazin-l-yl)-ethyl ester;
    2-Cyclohexyl-N-hydroxy-2-[{3-[4-(2-hydroxyethyl)piperazin30 1 -yl]-3-oxopropyl} -(4-methoxybenzenesulfonyl)amino]acetamide;
    AP/P/ 97 , u 10 78
    AP . Ο Ο 7 3 3
    -442-Hydroxy-2-[{3-[5-(2-hydroxyethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]-3-oxopropyl}-(4-methoxybenzenesulfonyl)amino]-3-methylbutyramide;
    2-{(4-Benzyloxybenzenesulfonyl)-[3-(4-hydroxypiperidin-l-yl)3-oxopropyl]amino}-N-hydroxy-3-methylbutyramide;
    5 2-Cyclohexyl-2-([4-(4-fluorophenoxy)benzenesulfonyl]-(3-(4-hydroxypiperidin-1 -yl)-3-oxopropyl]-amino}-N-hydroxyacetamide;
    2- {[4-(4-Butylphenoxy)benzenesulfonyl]-[3-(4-hydroxypiperidinl-yl)-3-oxopropyl]-amino}-N-hydroxy-3-methylbutyramide;
    l-{(4-Methoxybenzenesulfonyl)-[3-(4-methylaminopiperidin-l-yl)-3-oxo10 propyl]amino}-cyclopentanecarboxylic acid hydroxyamide;
    4-(3-((1 -Hydroxy carbamoyl-2-methylpropyl)-(4-methoxybenzenesulfonyl)amino]-propionyl}piperazine-2-carboxylic acid ethyl ester;
    3- [(Cyclohexylhydroxycarbamoylmethyl)-(4-methoxybenzenesulfonyl)amino]propionic acid ethoxycarbonyloxymethyl ester;
    15 3-((1 -Hydroxycarbamoylpentyl)-(4-methoxybenzenesulfonyl)amino]propionic acid ethoxycarbonyloxymethyl ester;
    1-(3-((1 -Hydroxycarbamoyl-2-methylpropyl)-(4-phenoxybenzenesulfonyl)amino] propionyl] piperidine-4-carboxylic acid.
    3-[[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-(l-hydroxy20 carbamoyl-2-methyl-propyl)-amino]-propionic acid ethoxycarbonyloxymethyl ester; and 3-[[4-(4-Fluorophenoxy)-benzenesulfonyl]-(l-hydroxycarbamoyl-2methyl-propyl)-amino]-propionic acid ethoxycarbonyloxymethyl ester.
  8. 8. A pharmaceutical composition for (a) the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, mucular
    25 degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, in combination with standard NS AID’S and analgesics and in combination with cytotoxic anti cancer agents, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) or (b) the inhibition of matrix metalloproteinases or the
    30 production of tumor necrosis factor (TNF) in a mammal, including a human,
    AP . Ο Ο 7 3 3
    -45comprising an amount of a compound of claim 1 effective in such treatment and a pharmaceutically acceptable carrier.
  9. 9. A method for the inhibition of (a) matrix metalloproteinases or (b) the production of tumor necrosis factor (TNF) in a mammal, including a human,
    5 comprising administering to said mammal an effective amount of a compound of claim 1.
  10. 10. A method for treating a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, compounds of formula I may be used in
    10 combination with standard NS AID’S and analgesics and in combination with cytotoxic anticancer agents, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (INF) in a mammal, including a human, comprising administering to said mammal an amount of a compound of claim 1, effective in treating such a
  11. 15 condition.
APAP/P/1997/001078A 1996-08-23 1997-08-21 Arylsulfonylamino hydroxamic acid derivatives. AP733A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2467596P 1996-08-23 1996-08-23

Publications (2)

Publication Number Publication Date
AP9701078A0 AP9701078A0 (en) 1997-10-31
AP733A true AP733A (en) 1999-02-12

Family

ID=21821806

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001078A AP733A (en) 1996-08-23 1997-08-21 Arylsulfonylamino hydroxamic acid derivatives.

Country Status (31)

Country Link
US (1) US6153609A (en)
EP (1) EP0922030A1 (en)
JP (1) JP2000501423A (en)
KR (1) KR20000068248A (en)
CN (1) CN1228083A (en)
AP (1) AP733A (en)
AR (1) AR009292A1 (en)
AU (1) AU711585B2 (en)
BG (1) BG103191A (en)
BR (1) BR9711223A (en)
CA (1) CA2264284A1 (en)
CO (1) CO4600003A1 (en)
EA (1) EA199900139A1 (en)
GT (1) GT199700094A (en)
HN (1) HN1997000110A (en)
HR (1) HRP970453A2 (en)
ID (1) ID18063A (en)
IL (1) IL128189A0 (en)
IS (1) IS4958A (en)
MA (1) MA24307A1 (en)
NO (1) NO990821L (en)
OA (1) OA10978A (en)
PA (1) PA8435301A1 (en)
PE (1) PE99698A1 (en)
PL (1) PL331895A1 (en)
SK (1) SK21499A3 (en)
TN (1) TNSN97139A1 (en)
TR (1) TR199900387T2 (en)
TW (1) TW397823B (en)
WO (1) WO1998007697A1 (en)
ZA (1) ZA977561B (en)

Families Citing this family (317)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69626684T2 (en) * 1995-12-08 2004-04-29 Agouron Pharmaceuticals, Inc., La Jolla METAL PROTEINASE INHIBITORS, THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AND THEIR PHARMACEUTICAL USE AND METHOD FOR THE PRODUCTION THEREOF
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
AU7294098A (en) * 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
EP0895988B1 (en) * 1997-08-08 2002-05-22 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
PA8469601A1 (en) * 1998-04-10 2000-09-29 Pfizer Prod Inc PROCEDURE FOR RENTING STERICALLY IMPAIRED SULFONAMIDES
PT952148E (en) * 1998-04-10 2004-09-30 Pfizer Prod Inc CYLOBUTIL-ARYLOXYARILSULFONYLAMINO-HYDROXYMIC ACID DERIVATIVES
GT199900044A (en) * 1998-04-10 2000-09-14 PROCEDURES FOR PREPARING PHENOXYPHENYL SULFONYL HALIDES.
PA8469301A1 (en) 1998-04-10 2000-09-29 Pfizer Prod Inc PROCEDURES FOR THE PREPARATION OF HYDROXAMIC ACIDS.
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
BR0007784A (en) 1999-01-27 2002-02-05 American Cyanamid Co Compound, method for inhibiting pathological changes mediated by the enzyme that converts tnf-alpha (tace) into a mammal, pharmaceutical composition, and, process for preparing a compound
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
PT1041072E (en) * 1999-03-31 2003-11-28 Pfizer Prod Inc DIOXOCYCLOPENTIL HYDROXYM ACIDS
DE19920907A1 (en) * 1999-05-06 2000-11-09 Basf Ag Preparation of cyclohexylglycine ester derivatives comprises reacting cyclohexylglycine derivatives with methanesulfonic acid and benzyl alcohol derivative in organic solvent
UA74803C2 (en) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
SE0000382D0 (en) 2000-02-07 2000-02-07 Astrazeneca Ab New process
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
US6458822B2 (en) 2000-03-13 2002-10-01 Pfizer Inc. 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
EA012079B3 (en) 2001-01-05 2018-07-31 Пфайзер Инк. MONOCLONAL ANTIBODY TO RECEPTOR OF INSULIN-LIKE GROWTH FACTOR I (IGF-I) AND METHODS OF ITS APPLICATION
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
WO2003037852A1 (en) 2001-11-01 2003-05-08 Wyeth Holdings Corporation Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
PE20030701A1 (en) 2001-12-20 2003-08-21 Schering Corp COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
JP4313678B2 (en) * 2001-12-27 2009-08-12 大日本住友製薬株式会社 Hydroxamic acid derivative and MMP inhibitor containing the same
EP1483268A2 (en) 2002-03-01 2004-12-08 Pfizer Inc. Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
WO2003075959A1 (en) * 2002-03-08 2003-09-18 Novartis Ag Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer
CA2478374C (en) 2002-03-13 2009-01-06 Eli M. Wallace N3 alkylated benzimidazole derivatives as mek inhibitors
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
CA2510850A1 (en) 2002-12-19 2004-07-08 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
AU2003294917A1 (en) * 2002-12-20 2004-07-14 Novartis Ag Device and method for delivering mmp inhibitors
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
JP4695588B2 (en) 2003-02-26 2011-06-08 スージェン， インク． Amino heteroaryl compounds as protein kinase inhibitors
DK1606288T3 (en) * 2003-03-25 2009-10-05 Fournier Lab Sa Benzenesulfonamide derivatives, their method of preparation and their use in the treatment of pain
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTIBODIES DIRECTED TO c-MET
EP1656391B1 (en) 2003-08-13 2010-10-13 Pfizer Products Inc. Modified human igf-1r antibodies
ES2314444T3 (en) 2003-08-29 2009-03-16 Pfizer Inc. TIENOPIRIDINE-PHENYLACETAMIN AND ITS USEFUL DERIVATIVES AS NEW ANTIANGIOGEN AGENTS.
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
UA84175C2 (en) 2003-11-19 2008-09-25 Аррей Байофарма Инк. Heterocyclic mek inhibitors and use thereof
WO2006008639A1 (en) 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
ME01788B (en) 2004-08-26 2011-02-28 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
AU2006299902B2 (en) 2005-05-18 2012-11-01 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
CA2623125A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
TWI405756B (en) 2005-12-21 2013-08-21 Array Biopharma Inc Novel hydrogen sulphate
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
DE602007009663D1 (en) 2006-04-18 2010-11-18 Ardea Biosciences Inc PYRIDONE SULPHONAMIDES AND PYRIDENESULFAMIDES AS MEK INHIBITORS
WO2008075196A1 (en) 2006-12-15 2008-06-26 Pfizer Products Inc. Benzimidazole derivatives
BRPI0806898A2 (en) 2007-01-19 2015-07-14 Ardea Biosciences Inc Mek inhibitors
UA97834C2 (en) 2007-04-18 2012-03-26 Пфайзер Продактс Инк. Sulfonyl amide derivatives for the treatment of abnormal cell growth
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
UA99731C2 (en) 2007-07-30 2012-09-25 Ардеа Биосайенсис, Инк CRYSTAL POLYMORPH FORMS OF N- (ARLYMINO) SULPHONAMIDES AS MECHANISM INHIBITORS, COMPOSITION (OPTIONS) AND APPLICATIONS
JP5421925B2 (en) 2007-12-19 2014-02-19 ジェネンテック， インコーポレイテッド 5-Anilinoimidazopyridine and method of use
ES2387707T3 (en) 2007-12-21 2012-09-28 Genentech, Inc. Azaindolizines and use procedures
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007419A (en) 2008-01-04 2010-11-12 Intellikine Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS.
JP5547099B2 (en) 2008-03-14 2014-07-09 インテリカイン， エルエルシー Kinase inhibitors and methods of use
DK2271347T3 (en) 2008-03-28 2016-08-15 Hale Biopharma Ventures Llc Administration of benzodiazepine compositions
US8895546B2 (en) 2009-03-27 2014-11-25 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
EP2334701A4 (en) 2008-10-16 2014-01-08 Univ Pittsburgh FULLY HUMAN ANTIBODIES DIRECTED AGAINST ANTIGEN ASSOCIATED WITH HIGH MOLECULAR WEIGHT MELANOMA AND USES THEREOF
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
CA2750519C (en) 2009-02-05 2018-09-25 Immunogen, Inc. Benzodiazepine derivatives
US20100204221A1 (en) 2009-02-09 2010-08-12 Hariprasad Vankayalapati Pyrrolopyrimidinyl axl kinase inhibitors
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
EP2400990A2 (en) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In situ methods for monitoring the emt status of tumor cells in vivo
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010108652A1 (en) 2009-03-27 2010-09-30 Ardea Biosciences Inc. Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
JP2013500991A (en) 2009-07-31 2013-01-10 オーエスアイ・ファーマシューティカルズ，エルエルシー mTOR inhibitor and angiogenesis inhibitor combination therapy
IN2012DN01961A (en) 2009-08-17 2015-08-21 Intellikine Llc
EP2473500A2 (en) 2009-09-01 2012-07-11 Pfizer Inc. Benzimidazole derivatives
US9034861B2 (en) 2009-10-13 2015-05-19 Allomek Therapeutics Llc MEK inhibitors useful in the treatment of diseases
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
CA2779574C (en) 2009-11-05 2018-12-18 Rhizen Pharmaceuticals S.A. Novel kinase modulators
MX341687B (en) 2010-02-10 2016-08-30 Immunogen Inc Cd20 antibodies and uses thereof.
WO2011098971A1 (en) 2010-02-12 2011-08-18 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
EP2542893A2 (en) 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EA025281B9 (en) 2010-05-17 2017-08-31 Инкозен Терапьютикс Пвт. Лтд. 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-b]PYRIDINE AND 3,5-DISUBSTITUED-3H-[1,2,3]TRIAZOLO[4,5-b]PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES
CN103002738A (en) 2010-05-21 2013-03-27 英特利凯恩有限责任公司 Chemical compounds, compositions and methods for kinase modulation
ES2611479T3 (en) 2010-06-16 2017-05-09 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Endoplasmin antibodies and their use
EP2630134B9 (en) 2010-10-20 2018-04-18 Pfizer Inc Pyridine-2- derivatives as smoothened receptor modulators
JP2013545749A (en) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds and uses thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
SG191965A1 (en) 2011-02-15 2013-08-30 Immunogen Inc Methods of preparation of conjugates
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
CA3019531A1 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
AP4075A (en) 2011-05-04 2017-03-23 Rhizen Pharmaceuticals S A Novel compounds as modulators of protein kinases
TWI565709B (en) 2011-07-19 2017-01-11 英菲尼提製藥股份有限公司 Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
SG11201400310WA (en) 2011-08-29 2014-06-27 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
CN102408411B (en) * 2011-09-19 2014-10-22 北京康辰药业股份有限公司 Hydroximic acid compound containing quinolyl and preparation method thereof, and drug composition containing the compound and use thereof
EP2758402B9 (en) 2011-09-22 2016-09-14 Pfizer Inc Pyrrolopyrimidine and purine derivatives
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2013050725A1 (en) 2011-10-04 2013-04-11 King's College London Ige anti -hmw-maa antibody
CN104271599A (en) 2011-11-08 2015-01-07 辉瑞公司 Methods of treating inflammatory disorders using anti-M-CSF antibodies
US9452215B2 (en) 2012-02-22 2016-09-27 The Regents Of The University Of Colorado Bourvadin derivatives and therapeutic uses thereof
ES2668044T3 (en) 2012-02-22 2018-05-16 The Regents Of The University Of Colorado, A Body Corporate Bouvardine derivatives and therapeutic uses thereof
CN104321322A (en) 2012-03-30 2015-01-28 理森制药股份公司 Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridines and 3,5-disubstituted-3H-[1,2,3]triazolo[ 4,5-B]pyridine compounds
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
ES2611788T3 (en) 2012-06-26 2017-05-10 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates thereof, methods for their preparation and methods for use
WO2014031566A1 (en) 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
HRP20190878T1 (en) 2012-08-31 2019-07-26 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
WO2014062838A2 (en) 2012-10-16 2014-04-24 Tolero Pharmaceuticals, Inc. Pkm2 modulators and methods for their use
MX386085B (en) 2012-11-01 2025-03-18 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
EP2961434A2 (en) 2013-02-28 2016-01-06 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP2961435B1 (en) 2013-02-28 2019-05-01 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
CA2905993C (en) 2013-03-14 2022-12-06 Tolero Pharmaceuticals, Inc. Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
EP3401314B1 (en) 2013-03-15 2023-11-08 Araxes Pharma LLC Covalent inhibitors of kras g12c
WO2014143659A1 (en) 2013-03-15 2014-09-18 Araxes Pharma Llc Irreversible covalent inhibitors of the gtpase k-ras g12c
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
CA2914284A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
ES2658039T3 (en) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods for their preparation and methods of use
CN105636586B (en) 2013-10-03 2018-05-29 库拉肿瘤学公司 ERK inhibitors and methods of use
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN105793255B (en) 2013-10-04 2018-11-16 无限药品股份有限公司 Heterocyclic compounds and their uses
TWI659021B (en) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Inhibitors of kras g12c
CA2926328C (en) 2013-10-10 2022-11-29 Araxes Pharma Llc Substituted quinazolinyl and quinolinyl derivatives and pharmaceutical compositions thereof useful as inhibitors of kras g12c
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UA115388C2 (en) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
PE20161436A1 (en) 2014-04-30 2017-01-08 Pfizer DIHETERO CYCLE DERIVATIVES LINKED TO CYCLOALKYL
HRP20190407T1 (en) 2014-06-19 2019-05-03 Ariad Pharmaceuticals, Inc. HETEROaryl Compounds for Inhibition of Kinases
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
EP3473271B1 (en) 2014-07-31 2022-07-20 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Human monoclonal antibodies against epha4 and their use
JO3556B1 (en) 2014-09-18 2020-07-05 Araxes Pharma Llc Combination therapies for treatment of cancer
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
EP3197870B1 (en) 2014-09-25 2020-08-19 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
JP6621477B2 (en) 2014-12-18 2019-12-18 ファイザー・インク Pyrimidine and triazine derivatives and their use as AXL inhibitors
EA201792214A1 (en) 2015-04-10 2018-01-31 Араксис Фарма Ллк COMPOUNDS OF SUBSTITUTE QUINAZOLINE
CA2982360A1 (en) 2015-04-15 2016-10-20 Liansheng Li Fused-tricyclic inhibitors of kras and methods of use thereof
WO2016172214A1 (en) 2015-04-20 2016-10-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
EP3288957A4 (en) 2015-05-01 2019-01-23 Cocrystal Pharma, Inc. NUCLEOSIDE ANALOGUES FOR USE IN THE TREATMENT OF FLAVIVIRIDAE AND CANCER FAMILY VIRUS INFECTIONS
DK3527574T3 (en) 2015-05-18 2022-06-27 Sumitomo Pharma Oncology Inc ALVOCIDIB PRODUCTS THAT HAVE INCREASED BIO-AVAILABILITY
TWI703150B (en) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 Methods and compositions for inhibiting the interaction of menin and mll proteins
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
AU2016301315C1 (en) 2015-08-03 2022-07-07 Sumitomo Pharma Oncology, Inc. Combination therapies for treatment of cancer
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356351A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3364977A4 (en) 2015-10-19 2019-09-04 Araxes Pharma LLC METHOD FOR SCREENING RAS INHIBITORS
KR20180081596A (en) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 Substituted quinazoline compounds comprising substituted heterocyclic groups and methods for their use
JP6877429B2 (en) 2015-12-03 2021-05-26 アジオス ファーマシューティカルズ， インコーポレイテッド MAT2A inhibitor for treating MTAP null cancer
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
BR112018015238A2 (en) 2016-01-27 2018-12-18 Sutro Biopharma Inc antibody conjugate, antibody, kit, pharmaceutical composition, and methods for treating or preventing a disease or condition and for diagnosing a disease or condition
TWI747889B (en) 2016-03-16 2021-12-01 美商庫拉腫瘤技術股份有限公司 Substituted inhibitors of menin-mll and methods of use
SG11201807834WA (en) 2016-03-16 2018-10-30 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
CN109414596B (en) 2016-05-12 2023-09-29 密歇根大学董事会 ASH1L inhibitors and methods of treatment therewith
US11118233B2 (en) 2016-05-18 2021-09-14 The University Of Chicago BTK mutation and ibrutinib resistance
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018045379A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
CN110036010A (en) 2016-09-29 2019-07-19 亚瑞克西斯制药公司 Inhibitors of KRAS G12C muteins
WO2018068017A1 (en) 2016-10-07 2018-04-12 Araxes Pharma Llc Heterocyclic compounds as inhibitors of ras and methods of use thereof
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
CA3047557A1 (en) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
SG11201906223TA (en) 2016-12-22 2019-08-27 Amgen Inc Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
CN110461872B (en) 2017-01-26 2023-09-26 再鼎医药(上海)有限公司 CD47 antigen binding units and uses thereof
JP7327802B2 (en) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー Fused hetero-heterobicyclic compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
CN110382483A (en) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 Condensed N- heterocyclic compound and its application method
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
CN117298275A (en) 2017-03-24 2023-12-29 库拉肿瘤学公司 Method for treating hematological malignancies and ewing's sarcoma
JOP20190272A1 (en) 2017-05-22 2019-11-21 Amgen Inc Kras g12c inhibitors and methods of using the same
WO2018218071A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
EP3630747A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Quinazoline derivatives as modulators of mutant kras, hras or nras
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
US20200207859A1 (en) 2017-07-26 2020-07-02 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
UY37870A (en) 2017-09-08 2019-03-29 Amgen Inc KRAS G12C INHIBITORS AND METHODS TO USE THEM FIELD OF THE INVENTION
JP7196160B2 (en) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Treatment Regimens for Cancers Insensitive to BCL-2 Inhibitors Using the MCL-1 Inhibitor Albocidib
SG11202002310UA (en) 2017-09-18 2020-04-29 Sutro Biopharma Inc Anti- folate receptor alpha antibody conjugates and their uses
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
US20200237766A1 (en) 2017-10-13 2020-07-30 Tolero Pharmaceuticals, Inc. Pkm2 activators in combination with reactive oxygen species for treatment of cancer
CA3082086A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
AU2018378935B2 (en) 2017-12-07 2024-10-31 The Regents Of The University Of Michigan NSD family inhibitors and methods of treatment therewith
CA3096984A1 (en) 2018-04-05 2019-10-10 Sumitomo Dainippon Pharma Oncology, Inc. Axl kinase inhibitors and use of the same
MA52501A (en) 2018-05-04 2021-03-10 Amgen Inc KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE
CA3099118A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
MX2020011907A (en) 2018-05-10 2021-01-29 Amgen Inc Kras g12c inhibitors for the treatment of cancer.
AU2019278998B2 (en) 2018-06-01 2023-11-09 Amgen Inc. KRAS G12C inhibitors and methods of using the same
EP3813784B1 (en) 2018-06-07 2024-01-10 The Regents Of The University Of Michigan Prc1 inhibitors and prc1 inhibitors for use in methods of treatment therewith
JP7357644B2 (en) 2018-06-11 2023-10-06 アムジエン・インコーポレーテツド KRAS G12C inhibitors for treating cancer
AU2019336588B2 (en) 2018-06-12 2022-07-28 Amgen Inc. KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
JP2021530554A (en) 2018-07-26 2021-11-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド Methods and ACVR1 Inhibitors for Treatment of Diseases with Abnormal ACVR1 Expression
CA3107168A1 (en) 2018-08-01 2020-02-06 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
EP3852811A1 (en) 2018-09-17 2021-07-28 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
KR20210083286A (en) 2018-10-24 2021-07-06 아락세스 파마 엘엘씨 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1H-indazol-4-yl as inhibitor of G12C mutant KRAS protein to inhibit tumor metastasis )-benzonitrile derivatives and related compounds
JP7516029B2 (en) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Improved synthesis of key intermediates for KRAS G12C inhibitor compounds
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7377679B2 (en) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
EP3887373A1 (en) 2018-11-29 2021-10-06 Araxes Pharma LLC Compounds and methods of use thereof for treatment of cancer
WO2020117988A1 (en) 2018-12-04 2020-06-11 Tolero Pharmaceuticals, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
ES2996960T3 (en) 2018-12-20 2025-02-13 Amgen Inc Heteroaryl amides useful as kif18a inhibitors
US12441736B2 (en) 2018-12-20 2025-10-14 Amgen Inc. KIF18A inhibitors
EP3897855B1 (en) 2018-12-20 2023-06-07 Amgen Inc. Kif18a inhibitors
JOP20210154B1 (en) 2018-12-20 2023-09-17 Amgen Inc KIF18A inhibitors
EP3924351B1 (en) 2019-02-12 2025-05-21 Sumitomo Pharma America, Inc. Crystalline form of the hydrochloride salt of 2-((1r,4r)-4-((3-(3-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol
WO2020180770A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
US20230148450A9 (en) 2019-03-01 2023-05-11 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
US11712433B2 (en) 2019-03-22 2023-08-01 Sumitomo Pharma Oncology, Inc. Compositions comprising PKM2 modulators and methods of treatment using the same
EP3962951A1 (en) 2019-05-03 2022-03-09 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
CR20210665A (en) 2019-05-21 2022-01-25 Amgen Inc Solid state forms
CN114302878A (en) 2019-07-03 2022-04-08 大日本住友制药肿瘤公司 Tyrosine kinase non-receptor 1(TNK1) inhibitors and uses thereof
CN114302880B (en) 2019-08-02 2025-07-15 美国安进公司 KIF18A inhibitors
CN114391012B (en) 2019-08-02 2025-10-31 美国安进公司 Pyridine derivatives as KIF18A inhibitors
US20220281843A1 (en) 2019-08-02 2022-09-08 Amgen Inc. Kif18a inhibitors
WO2021026099A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021055728A1 (en) 2019-09-18 2021-03-25 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
TW202126636A (en) 2019-09-30 2021-07-16 美商阿吉歐斯製藥公司 Piperidine compounds as menin inhibitors
EP4684786A2 (en) 2019-10-24 2026-01-28 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
CR20220230A (en) 2019-10-28 2022-06-15 Merck Sharp & Dohme SMALL MOLECULE INHIBITORS OF KRAS MUTANT G12C
CN119424423A (en) 2019-10-31 2025-02-14 大鹏药品工业株式会社 4-Aminobut-2-enamide derivatives and salts thereof
CA3160142A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
US11739074B2 (en) 2019-11-04 2023-08-29 Revolution Medicines, Inc. Ras inhibitors
CN120988055A (en) 2019-11-04 2025-11-21 锐新医药公司 RAS inhibitors
JP7812056B2 (en) 2019-11-08 2026-02-09 レヴォリューション・メディスンズ，インコーポレイテッド Bicyclic heteroaryl compounds and uses thereof
TWI882037B (en) 2019-11-14 2025-05-01 美商安進公司 Improved synthesis of kras g12c inhibitor compound
AU2020383535A1 (en) 2019-11-14 2022-05-05 Amgen Inc. Improved synthesis of KRAS G12C inhibitor compound
CN114980976A (en) 2019-11-27 2022-08-30 锐新医药公司 Covalent RAS inhibitors and uses thereof
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
BR112022010086A2 (en) 2020-01-07 2022-09-06 Revolution Medicines Inc SHP2 INHIBITOR DOSAGE AND CANCER TREATMENT METHODS
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
WO2021178597A1 (en) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
WO2021204159A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
TW202204334A (en) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin inhibitors and methods of use for treating cancer
US20230181536A1 (en) 2020-04-24 2023-06-15 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
US20230174518A1 (en) 2020-04-24 2023-06-08 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
TW202214253A (en) 2020-06-18 2022-04-16 美商銳新醫藥公司 Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
CN116113406B (en) 2020-07-10 2025-08-29 密歇根大学董事会 GAS41 inhibitors and methods of use
TW202216151A (en) 2020-07-15 2022-05-01 日商大鵬藥品工業股份有限公司 Pyrimidine compound-containing combination to be used in tumor treatment
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
MX2023003060A (en) 2020-09-15 2023-04-05 Revolution Medicines Inc Indole derivatives as ras inhibitors in the treatment of cancer.
TW202237119A (en) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk-5 inhibitors and uses thereof
EP4267250A1 (en) 2020-12-22 2023-11-01 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
KR102868758B1 (en) 2021-04-13 2025-10-14 뉴베일런트, 아이엔씨. Amino-substituted heterocycles for treating cancers harboring EGFR mutations
US11931420B2 (en) 2021-04-30 2024-03-19 Celgene Corporation Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
TW202309053A (en) 2021-05-05 2023-03-01 美商銳新醫藥公司 Ras inhibitors
IL308193A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc Ras inhibitors
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
JP2024521979A (en) 2021-05-28 2024-06-04 大鵬薬品工業株式会社 CROSS-REFERENCE TO RELATED APPLICATIONS SMALL MOLECULE INHIBITORS OF KRAS MUTANT PROTEINS
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
WO2023064058A1 (en) 2021-10-12 2023-04-20 Peloton Therapeutics Inc. Tricyclic sultams and sulfamides as antitumor agents
US20250282782A1 (en) 2021-12-17 2025-09-11 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4490146B1 (en) 2022-03-07 2026-02-18 Amgen Inc. A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
CN119136806A (en) 2022-03-08 2024-12-13 锐新医药公司 Methods for treating immune-refractory lung cancer
WO2023211812A1 (en) 2022-04-25 2023-11-02 Nested Therapeutics, Inc. Heterocyclic derivatives as mitogen-activated protein kinase (mek) inhibitors
JP2025521232A (en) 2022-06-10 2025-07-08 レボリューション メディシンズ インコーポレイテッド Macrocyclic RAS inhibitors
TW202408589A (en) 2022-06-30 2024-03-01 美商舒卓生物製藥公司 Anti-ror1 antibodies and antibody conjugates, compositions comprising anti‑ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
MA71389A (en) 2022-07-08 2025-04-30 Nested Therapeutics, Inc. MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS
GEAP202516749A (en) 2022-10-14 2025-07-25 Black Diamond Therapeutics Inc Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
EP4688790A1 (en) 2023-04-07 2026-02-11 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
KR20250172857A (en) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Crystalline form of RAS inhibitor
KR20250169290A (en) 2023-04-14 2025-12-02 레볼루션 메디슨즈, 인크. Crystalline form of RAS inhibitor, composition containing same and method of use thereof
AU2024262795A1 (en) 2023-04-24 2025-11-13 Nested Therapeutics, Inc. Heterocyclic derivative as mitogen-activated protein kinase (mek) inhibitor
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025043187A1 (en) 2023-08-24 2025-02-27 Otsuka Pharmaceutical Co., Ltd. Fixed dose combinations of cedazuridine and azacitidine
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025081117A2 (en) 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
TW202535891A (en) 2023-10-20 2025-09-16 美商默沙東有限責任公司 Small molecule inhibitors of kras proteins
WO2025090905A1 (en) 2023-10-26 2025-05-01 Nested Therapeutics, Inc. Crystalline forms of 3-[[3-fluoro-2-(methylsulfamoylamino)-4-pyridyl]methyl]-7-[(3-fluoro-2-pyridyl)oxy]-4-methyl-chromen-2-one
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025250825A1 (en) 2024-05-30 2025-12-04 Sutro Biopharma, Inc. Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025259841A1 (en) 2024-06-13 2025-12-18 Nested Therapeutics, Inc. Crystalline forms of 3-[[3-fluoro-2-(methylsulfamoylamino)-4-pyridyl]jmethyl]-7-[(3-fluoro-2-pyridyl)oxy]-4-methyl-chromen-2-one
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0606046A1 (en) * 1993-01-06 1994-07-13 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids
WO1996000214A1 (en) * 1994-06-24 1996-01-04 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
ATE191468T1 (en) * 1994-06-22 2000-04-15 British Biotech Pharm METALLOPROTEINASE INHIBITORS
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
BR9609883A (en) * 1995-08-08 1999-03-23 Fibrogen Inc Compound having inhibitory effect on proteinase and pharmaceutical composition and process to treat diseases related to inappropriate or unregulated collagen production
US5994351A (en) * 1998-07-27 1999-11-30 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0606046A1 (en) * 1993-01-06 1994-07-13 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids
WO1996000214A1 (en) * 1994-06-24 1996-01-04 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
OA10978A (en) 2001-11-05
HRP970453A2 (en) 1998-08-31
NO990821L (en) 1999-02-23
IS4958A (en) 1999-01-26
SK21499A3 (en) 2000-05-16
BR9711223A (en) 1999-08-17
US6153609A (en) 2000-11-28
AP9701078A0 (en) 1997-10-31
KR20000068248A (en) 2000-11-25
IL128189A0 (en) 1999-11-30
AR009292A1 (en) 2000-04-12
AU711585B2 (en) 1999-10-14
PE99698A1 (en) 1998-12-26
TNSN97139A1 (en) 2005-03-15
EP0922030A1 (en) 1999-06-16
ZA977561B (en) 1999-02-22
NO990821D0 (en) 1999-02-22
MA24307A1 (en) 1998-04-01
GT199700094A (en) 1999-02-10
EA199900139A1 (en) 1999-08-26
CN1228083A (en) 1999-09-08
CA2264284A1 (en) 1998-02-26
PA8435301A1 (en) 1999-12-27
CO4600003A1 (en) 1998-05-08
PL331895A1 (en) 1999-08-16
HN1997000110A (en) 1998-02-26
TW397823B (en) 2000-07-11
TR199900387T2 (en) 1999-04-21
ID18063A (en) 1998-02-26
WO1998007697A1 (en) 1998-02-26
JP2000501423A (en) 2000-02-08
BG103191A (en) 1999-11-30
AU3456397A (en) 1998-03-06

Similar Documents

Publication Publication Date Title
AP733A (en) Arylsulfonylamino hydroxamic acid derivatives.
AP958A (en) Arylsulfonyl hydroxamic acid derivatives.
EP0821671B1 (en) Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
AP826A (en) Arysulfonylamino hydroxamic acid derivatives.
EP0813520B1 (en) Arylsulfonylamino hydroxamic acid derivatives
EP0895988B1 (en) Arylsulfonylamino hydroxamic acid derivatives
WO1998034915A1 (en) N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
US6380219B1 (en) Arylsulfonylamino hydroxamic acid derivatives
US6509337B1 (en) Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
US6107337A (en) Arylsulfonylamino hydroxamic acid derivatives
MXPA99001808A (en) Arylsulfonylamino hydroxamic acid derivatives
KR100194258B1 (en) Arylsulfonyl Hydroxamic Acid Derivatives
CZ58999A3 (en) Derivatives of arylsulfonylaminohydroxamic acid, pharmaceutical preparation, inhibition method of matrix metalloproteinases or production of tumor necrosis factor and therapeutical method
MXPA99006301A (en) Cyclic sulfone derivatives